

CITATION REPORT

List of articles citing

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

DOI: 10.1016/j.ccr.2005.03.023
Cancer Cell, 2005, 7, 387-97.

Source: <https://exaly.com/paper-pdf/38252261/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2340	Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan. 2014 , 30, 185-8		5
2339	Reactive and clonal thrombocytosis. 2001 , 186-200		
2338	Variation of the phenotype induced by the Gata1 ^{low} mutation in mice of different genetic backgrounds. 2005 , 106, 4102-13		28
2337	The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. 2005 , 106, 2862-4		94
2336	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. 2005 , 106, 2921-2		81
2335	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. 2005 , 106, 3374-6		148
2334	Signal transduction of oncogenic Flt3. 2005 , 82, 93-9		69
2333	The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. 2005 , 130, 800-1		49
2332	The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. 2005 , 130, 964-5		27
2331	JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia. 2005 , 130, 968		25
2330	Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. 2005 , 131, 166-71		70
2329	JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. 2005 , 131, 208-13		257
2328	The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. 2005 , 131, 320-8		191
2327	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 2005 , 19, 1847-9		212
2326	Myeloproliferative disorders: the centrosome connection. 2005 , 19, 1739-44		25
2325	The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. 2005 , 19, 2359-60		42
2324	The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. 2005 , 24, 7248-52		104

2323	JAK the trigger. 2005 , 24, 7125-6	4
2322	Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8. 2005 , 33, 1299-308	11
2321	Conventional and new treatment options for myelofibrosis with myeloid metaplasia. 2005 , 32, 422-31	6
2320	The V617F JAK2 mutation and the myeloproliferative disorders. 2005 , 23, 91-3	29
2319	Quantification of clonal hematopoiesis in polycythemia vera. 2005 , 447, 947-53	3
2318	Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies. 2005 , 447, 909-19	23
2317	[A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]. 2005 , 21, 669-70	13
2316	Fostering innovation and discovery in biomedical research. 2005 , 294, 1390-3	18
2315	Janus kinases affect thrombopoietin receptor cell surface localization and stability. 2005 , 280, 27251-61	122
2314	JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. 2005 , 280, 41893-9	128
2313	Anagrelide for control of thrombocytosis due to myeloproliferative disorders. 2005 , 1, 609-18	4
2312	JAK2 mutations in myeloproliferative disorders. 2005 , 353, 1416-7; author reply 1416-7	67
2311	Molecular Pathogenesis of MDS. 2005 , 2005, 156-60	43
2310	Management of polycythemia vera and essential thrombocythemia. 2005 , 2005, 201-8	35
2309	Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. 2005 , 165, 2651-8	81
2308	A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. 2005 , 2005, 195-200	75
2307	When and how to treat essential thrombocythemia. 2005 , 353, 85-6	66
2306	Platelets and thrombosis in myeloproliferative diseases. 2005 , 409-15	42

2305	Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. 2005 , 102, 18962-7	263
2304	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. 2005 , 106, 3370-3	312
2303	Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. 2006 , 125, 253-64	21
2302	JAK2 in Myeloproliferative Disorders Is Not Just Another Kinase. 2005 , 4, 4053-4056	48
2301	Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond. 2005 , 10 Suppl 1, 215-23	9
2300	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. 2005 , 366, 1945-53	557
2299	Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. 2005 , 65, 9152-4	204
2298	The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. 2005 , 106, 2920-1	133
2297	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. 2005 , 106, 3377-9	319
2296	Importance of molecular confirmation in the diagnosis of myeloproliferative disorders. 2005 , 2, 418-422	
2295	Essential thrombocythemia. 2005 , 42, 230-8	39
2294	Chromosomal abnormalities and molecular markers in myeloproliferative disorders. 2005 , 42, 196-205	21
2293	Lessons from familial myeloproliferative disorders. 2005 , 42, 266-73	41
2292	Chronic myeloproliferative disorders--introduction. 2005 , 42, 181-3	7
2291	Idiopathic myelofibrosis. 2005 , 42, 248-58	30
2290	bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. 2005 , 80, 1220-32	36
2289	Pathogenesis of myelofibrosis with myeloid metaplasia. 2005 , 23, 8520-30	211
2288	The molecular mechanisms that control thrombopoiesis. 2005 , 115, 3339-47	365

2287	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. 2005 , 106, 2162-8	706
2286	A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. 2005 , 11, 546-54	92
2285	Resistance to tyrosine kinase inhibitors: calling on extra forces. 2005 , 8, 119-29	33
2284	Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 2005 , 167, 849-58	53
2283	Role of tyrosine kinases and phosphatases in polycythemia vera. 2005 , 42, 221-9	21
2282	Polycythemia vera: scientific advances and current practice. 2005 , 42, 206-20	52
2281	Myelofibrosis with myeloid metaplasia: where is the biology leading us?. 2005 , 32, 357-8	
2280	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. 2005 , 106, 1207-9	399
2279	Identification of an acquired JAK2 mutation in polycythemia vera. 2005 , 280, 22788-92	477
2278	Myeloid Leukemia. 2005 ,	
2277	Genetics of myeloid malignancies: pathogenetic and clinical implications. 2005 , 23, 6285-95	281
2276	The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. 2005 , 80, 947-58	101
2275	Current Treatment Approaches of Polycythemia Vera. 2006 , 1, 41-45	
2274	The myelodysplastic syndromes: diagnosis and treatment. 2006 , 81, 104-30	145
2273	Atypical myeloproliferative disorders: diagnosis and management. 2006 , 81, 553-63	38
2272	Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis. 2006 , 10, 311-7	5
2271	JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?. 2006 , 47, 177-94	43
2270	JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. 2006 , 47, 313-4	25

2269	Experimental therapy in myelofibrosis with myeloid metaplasia. 2006 , 15, 1555-63	3
2268	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. 2006 , 108, 346-52	195
2267	A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. 2006 , 47, 381-96	38
2266	Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. 2006 , 169, 471-81	33
2265	JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. 2006 , 8, 397-411; quiz 526	65
2264	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. 2006 , 107, 3676-82	214
2263	Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. 2006 , 2006, 233-9, 510	41
2262	Myelodysplastic/Myeloproliferative Disorder Overlap Syndrome: How Should it be Approached?. 2006 , 1, 95-100	1
2261	Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. 2006 , 8, 170-7	24
2260	Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. 2006 , 130, 2031-8	238
2259	The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. 2006 , 107, 176-83	217
2258	[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders]. 2006 , 127, 601-4	0
2257	Recent advances in the bcr-abl negative chronic myeloproliferative diseases. 2006 , 4, 41	17
2256	Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. 2006 , 108, 1377-80	230
2255	Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. 2006 , 354, 2166-75	31
2254	Cross-regulation of JAK and Src kinases. 2006 , 24, 89-95	37
2253	Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. 2006 , 19, 365-85	30
2252	Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. 2006 , 19, 399-412	8

2251	Polycythemia vera and its molecular basis: an update. 2006 , 19, 387-97	6
2250	The diagnosis of polycythemia vera: new tests and old dictums. 2006 , 19, 455-69	10
2249	Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. 2006 , 19, 495-517	25
2248	Classic and atypical myeloproliferative disorders. 2006 , 19, 361-364	5
2247	Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. 2006 , 8, 330-4	23
2246	Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. 2006 , 8, 299-304	26
2245	No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. 2006 , 12, 1350-1	20
2244	Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. 2006 , 17, 423-30	10
2243	The myeloproliferative disorders. 2006 , 355, 2452-66	485
2242	Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocationReply. 2006 , 37, 500-502	6
2241	Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. 2006 , 37, 1458-64	16
2240	[Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy]. 2006 , 27, 473-7	0
2239	[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders]. 2006 , 54, 182-4	1
2238	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. 2006 , 38, 336-42	13
2237	Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. 2006 , 107, 2219-22	30
2236	The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. 2006 , 108, 1865-7	218
2235	Polycythemia vera erythroblasts: too tough to die. 2006 , 107, 3422-3423	
2234	Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. 2006 , 108, 3913-5	91

2233	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. 2006 , 111, 233-49	7
2232	Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. 2006 , 107, 907-15	143
2231	A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. 2006 , 107, 1237-8	17
2230	Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. 2006 , 107, 3495-502	43
2229	V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. 2006 , 107, 2098-100	181
2228	Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. 2006 , 107, 4214-22	112
2227	Screening and counseling for thalassemia. 2006 , 107, 1735-7	7
2226	Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. 2006 , 107, 4898-906	184
2225	Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. 2006 , 107, 1242-3	55
2224	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. 2006 , 107, 1733-5; author reply 1735	9
2223	X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. 2006 , 107, 4139-41	197
2222	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. 2006 , 107, 3339-41	107
2221	Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. 2006 , 108, 1684-9	63
2220	Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. 2006 , 108, 123-33	166
2219	STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. 2006 , 107, 4326-33	39
2218	Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. 2006 , 108, 3548-55	267
2217	Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. 2006 , 107, 4274-81	412
2216	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. 2006 , 108, 1652-60	362

2215	Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. 2006 , 108, 2173-81	168
2214	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). 2006 , 108, 1497-503	287
2213	High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. 2006 , 108, 2037-40	200
2212	JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. 2006 , 108, 2770-9	94
2211	Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. 2006 , 108, 3600-2	54
2210	Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. 2006 , 108, 3128-34	133
2209	Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. 2006 , 108, 2435-7	232
2208	From 1 to 2 mutated JAK2: the road from ET to PV. 2006 , 108, 2140-2141	
2207	Thrombocythmie essentielle. Critères du diagnostic. Stratification pronostique. Bauche de stratégie thérapeutique. 2006 , 1, 1-19	0
2206	Current World Literature. 2006 , 18, 83-105	
2205	Chromosomal translocations in cancer and their relevance for therapy. 2006 , 18, 62-8	17
2204	The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. 2006 , 132, 244-5	124
2203	Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. 2006 , 134, 341-3	14
2202	The role of Janus kinases in haemopoiesis and haematological malignancy. 2006 , 134, 366-84	71
2201	GB976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. 2006 , 135, 303-16	71
2200	Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. 2006 , 25, 4763-72	62
2199	Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. 2006 , 20, 168-71	107
2198	Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. 2006 , 20, 55-60	53

2197	Chronic myeloproliferative disorders: a tyrosine kinase tale. 2006 , 20, 200-5	56
2196	Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. 2006 , 20, 350-3	116
2195	JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. 2006 , 20, 471-6	122
2194	JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. 2006 , 20, 534-5	40
2193	JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders. 2006 , 20, 736-7	7
2192	Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. 2006 , 20, 1168-9	7
2191	JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. 2006 , 20, 971-8	113
2190	A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. 2006 , 20, 1055-60	62
2189	The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. 2006 , 20, 1319-21	80
2188	The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. 2006 , 20, 1315-6	14
2187	Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. 2006 , 20, 1641-4	60
2186	Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. 2006 , 20, 2195-7	69
2185	Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. 2006 , 20, 1800-8	29
2184	Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. 2006 , 20, 1706-16	73
2183	JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. 2006 , 20, 1903-5	11
2182	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 2006 , 20, 2067-70	56
2181	Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. 2006 , 20, 2198-9	5
2180	The JAK2 V617F mutation in de novo acute myelogenous leukemias. 2006 , 25, 1434-6	145

2179	Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. 2006 , 25, 4573-84	32
2178	Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. 2006 , 30, 1217-25	25
2177	Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. 2006 , 30, 1097-104	51
2176	Mutation screening for JAK2V617F: when to order the test and how to interpret the results. 2006 , 30, 739-44	29
2175	JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. 2006 , 30, 1457-60	38
2174	AML: many new tools for discovery, not enough answers (yet). 2006 , 30, 1073-5	2
2173	SFK-STAT pathway: an alternative and important way to malignancies. 2006 , 1086, 213-22	22
2172	Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. 2006 , 85, 226-32	70
2171	Oncogenic mechanisms in myeloproliferative disorders. 2006 , 63, 2939-53	61
2170	Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). 2006 , 57, 145-64	87
2169	The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective. 2006 , 1, 75-80	3
2168	Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. 2006 , 81, 217-23	17
2167	Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. 2006 , 77, 57-60	15
2166	JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. 2006 , 77, 210-6	56
2165	STAT1 acts as a tumor promoter for leukemia development. <i>Cancer Cell</i> , 2006 , 10, 77-87	24.3 115
2164	Activating alleles of JAK3 in acute megakaryoblastic leukemia. <i>Cancer Cell</i> , 2006 , 10, 65-75	24.3 265
2163	JAK/STAT signal transduction: regulators and implication in hematological malignancies. 2006 , 71, 713-21	205
2162	Jaks and cytokine receptors--an intimate relationship. 2006 , 72, 1538-46	162

2161	TIPS, couverture et SBC PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome, M. Hernandez-Guerra, J. Turnes, P. Rubinstein, S. Olliff, E. Elias, J. Bosch, et al., in: Hepatology, 40 (2004), pp. 1197-1202. 2006 , 30, 1183-1184	
2160	Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation. 2006 , 77, 463-70	9
2159	Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. 2006 , 106, 623-30	46
2158	The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. 2006 , 106, 631-5	187
2157	Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. 2006 , 106, 1739-43	18
2156	Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. 2006 , 107, 451-8	116
2155	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. 2006 , 107, 2206-11	74
2154	Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. 2006 , 44, 1528-34	220
2153	Idiopathic myelofibrosis: pathogenesis to treatment. 2006 , 24, 56-63	20
2152	A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. 2006 , 24, 227-33	29
2151	Reexamination of the need for treatment in Idiopathic Thrombocytopenic Purpura. 2006 , 81, 803	
2150	Acute haemolytic transfusion reaction by Le(a) alloantibody. 2006 , 81, 807-8	1
2149	Successful corticosteroid therapy for epoetin-beta-induced pure red-cell aplasia in a hemodialysis patient. 2006 , 81, 803-4	2
2148	Primary bilateral diffuse renal lymphoma. 2006 , 81, 804-5	2
2147	Molecular misdiagnosis in type 2B von Willebrand disease. 2006 , 81, 805-6	2
2146	JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. 2006 , 81, 806-7	21
2145	Diagnostic Assays for the JAK2V617F Mutation in Chronic Myeloproliferative Disorders. 2006 , 125, 651-653	28
2144	2005: signaling breakthroughs of the year. 2006 , 2006, eg1	

2143	Point mutations of protein kinases and individualised cancer therapy. 2006 , 7, 2243-61	23
2142	New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. 2006 , 32, 341-51	30
2141	Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. 2006 , 20, 3321-35	35
2140	The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. 2006 , 32, 381-98	36
2139	Diagnosis and therapy of polycythemia vera. 2006 , 32, 267-75	5
2138	Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. 2006 , 32, 283-8	3
2137	Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. 2006 , 32, 174-207	78
2136	Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. 2006 , 32, 417-21	64
2135	Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. 2006 , 32, 208-18	47
2134	Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. 2006 , 32, 251-9	14
2133	The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. 2006 , 32, 307-40	42
2132	Practical management of classical myeloproliferative disorder patients: a clinician's guide. 2006 , 2, 515-24	1
2131	Developing target therapy against oncogenic tyrosine kinase in myeloid malignancies. 2006 , 7, 331-7	2
2130	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612	13
2129	Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. 2006 , 7, 185-98	2
2128	The JAK-STAT pathway: a therapeutic target in hematological malignancies. 2006 , 6, 671-9	68
2127	Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis. 2006 , 2, 169-186	1
2126	Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease. 2006 , 126, 789-797	35

2125	Absence of JAK2 V617F mutation in gastric cancers. 2006 , 45, 222-3	18
2124	Advances in the therapy of chronic idiopathic myelofibrosis. 2006 , 11, 929-43	22
2123	Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. 2006 , 126, 530-3	52
2122	Identification of the JAK2V617F Mutation in Chronic Myeloproliferative Disorders Using FRET Probes and Melting Curve Analysis. 2006 , 125, 625-633	59
2121	Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. 2006 , 26, 6381-94	34
2120	Characterization of murine JAK2V617F-positive myeloproliferative disease. 2006 , 66, 11156-65	168
2119	Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. 2006 , 6, 107-21	145
2118	An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. 2006 , 177, 4907-16	23
2117	Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. 2006 , 66, 9714-21	128
2116	SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. 2006 , 12, 6844-52	64
2115	Nonmalignant portal vein thrombosis in adults. 2006 , 3, 505-15	86
2114	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. 2006 , 108, 3472-6	833
2113	Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. 2006 , 103, 16930-5	27
2112	Activated Jak2 with the V617F point mutation promotes G1/S phase transition. 2006 , 281, 18177-83	78
2111	Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. 2006 , 176, 6425-33	20
2110	The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. 2006 , 103, 6224-9	226
2109	Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. 2006 , 26, 4052-62	46
2108	Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. 2006 , 2006, 240-5	58

2107	Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. 2007 , 2007, 355-62	11
2106	Oncogenes in myeloproliferative disorders. 2007 , 6, 550-66	129
2105	Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. 2007 , 25, 1048-53	94
2104	Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. 2007 , 282, 3428-32	88
2103	8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. 2007 , 72, 1137-45	34
2102	Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis. 2007 , 99, 223-35	25
2101	JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism. 2007 , 293, F1836-46	20
2100	Ba/F3 cells and their use in kinase drug discovery. 2007 , 19, 55-60	141
2099	Human Leukocyte and Granulocyte Antigens and Antibodies: The HLA and HNA Systems. 2007 , 129-156	
2098	The genetic basis of myeloproliferative disorders. 2007 , 2007, 1-10	33
2097	Advances in molecular diagnostics of myeloproliferative disorders. 2007 , 1, 65-80	
2096	Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. 2008 , 36, 148-59	32
2095	Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. 2007 , 33, 313-20	157
2094	Modern Hematology. 2007 ,	15
2093	JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. 2007 , 127, 736-43	38
2092	A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. 2007 , 127, 977-81	21
2091	SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. 2008 , 17, 1031-42	153
2090	Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. 2007 , 67, 6417-24	58

2089	Functional conservation of erythropoietin signaling in zebrafish. 2007 , 110, 2718-26	99
2088	Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. 2007 , 44, 412-6	37
2087	Comparative evaluation of three JAK2V617F mutation detection methods. 2007 , 128, 865-74	20
2086	Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. 2007 , 104, 18502-7	52
2085	Pathophysiology of and Therapy for Primary Myelofibrosis. 2007 , 96, 1724-1732	
2084	Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. 2007 , 3, 315-24	12
2083	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. 2007 , 109, 1678-86	103
2082	High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x10 ⁹ /L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. 2007 , 109, 1334-5	54
2081	How I treat patients with polycythemia vera. 2007 , 109, 5104-11	88
2080	Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. 2007 , 110, 3735-43	84
2079	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. 2007 , 109, 71-7	135
2078	JAK2(V617F): Prevalence in a large Chinese hospital population. 2007 , 109, 339-42	124
2077	The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. 2007 , 109, 4924-9	104
2076	Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. 2007 , 110, 345-53	43
2075	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. 2007 , 110, 1013-21	152
2074	JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation. 2007 , 110, 1675-80	7
2073	Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. 2007 , 110, 375-9	271
2072	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 2007 , 110, 840-6	368

2071	Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. 2007 , 110, 719-26	170
2070	Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. 2007 , 110, 354-9	65
2069	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. 2007 , 110, 1092-7	715
2068	A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. 2007 , 110, 2768-9	42
2067	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. 2007 , 110, 4030-6	207
2066	Thrombocytosis and thrombosis. 2007 , 363-70	56
2065	Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. 2007 , 14, 688-93	55
2064	JAK2 mutations and clinical practice in myeloproliferative neoplasms. 2007 , 13, 366-71	26
2063	From the Guest Editors. 2007 , 13, 355-356	
2062	Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. 2007 , 31, 233-9	42
2061	Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. 2007 , 83, 1518-20	26
2060	Bibliography. Current world literature. Endocrine tumours. 2007 , 19, 65-9	
2059	Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. 2007 , 19, 628-34	7
2058	The diagnostic interface between histology and molecular tests in myeloproliferative disorders. 2007 , 14, 115-22	25
2057	Molecular insights into stress erythropoiesis. 2007 , 14, 215-24	95
2056	JAK2 V617F: implications for thrombosis in myeloproliferative diseases. 2007 , 14, 450-4	21
2055	Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. 2007 , 8, 205-16	25
2054	Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?. 2007 , 2, 253-63	2

2053	JAK-2 mutations and their relevance to myeloproliferative disease. 2007 , 14, 43-7	41
2052	The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways. 2007 , 14, 9-15	22
2051	Anomalies chromosomiques et gñiques dans les hñmopathies malignes. 2007 , 2, 1-13	
2050	Comparison of diagnostic criteria for polycythaemia vera. 2007 , 12, 123-30	7
2049	Defects in growth hormone receptor signaling. 2007 , 18, 134-41	122
2048	[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]. 2007 , 55, 49-55	3
2047	Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). 2007 , 55, 92-104	25
2046	JAK2, the JAK2 V617F mutant and cytokine receptors. 2007 , 55, 88-91	19
2045	Endogenous erythroid colony formation in patients with retinal vein occlusion. 2007 , 114, 2155-61	6
2044	Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. 2007 , 13, 64-72	22
2043	Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. 2007 , 13, 355-65	155
2042	Jak2: normal function and role in hematopoietic disorders. 2007 , 17, 8-14	117
2041	Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. 2007 , 255, 12-25	19
2040	Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. 2007 , 44, 2497-506	240
2039	Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. 2007 , 38, 1057-1064	31
2038	Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. 2007 , 38, 1760-3	17
2037	Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. 2007 , 81, 114-26	216
2036	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. 2007 , 8, 658-60	61

2035	Stochastic dynamics of hematopoietic tumor stem cells. 2007 , 6, 461-6	79
2034	Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. 2007 , 109, 1316-21	140
2033	Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders. 2007 , 70, 89-93	8
2032	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. 2007 , 356, 459-68	996
2031	Apoptosis, Senescence, and Cancer. 2007 ,	6
2030	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. 2007 , 109, 2202-4	103
2029	Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. 2007 , 109, 1241-3	54
2028	Acute Myelogenous Leukemia. 2007 ,	
2027	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. 2007 , 9, 272-6	54
2026	The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. 2007 , 110, 3384-6	42
2025	Head and Neck Manifestations of Systemic Disease. 2007 ,	2
2024	Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells. 2007 , 48, 134-46	12
2023	A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. 2007 , 48, 2189-95	21
2022	A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation. 2007 , 11, 463-6	5
2021	Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. 2007 , 98, 191-220	5
2020	Controversies in the Management of Essential Thrombocythemia. 2007 , 1, 155-161	
2019	Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. 2007 , 82, 599-604	25
2018	Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. 2007 , 74, 72-80	17

2017	Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification. 2007 , 74, 63-71	18
2016	Essential thrombocythemia. 2007 , 2, 3	66
2015	The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age. 2007 , 20, 5-12	18
2014	The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. 2007 , 92, 1607-14	70
2013	Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. 2007 , 118, 209-14	16
2012	Thrombocytosis: Essential Thrombocythemia and Reactive Causes. 2007 , 295-318	
2011	[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection]. 2007 , 148, 203-10	4
2010	JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit. 2007 , 92, 431-2	12
2009	SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. 2007 , 2, e1225	71
2008	Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. 2007 , 92, 137-8	35
2007	[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]. 2007 , 27, 77-82	3
2006	Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. 2007 , 82, 80-2	11
2005	Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders. 2007 , 82, 458-9	6
2004	Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors. 2007 , 121, 2113-5	3
2003	The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. 2007 , 109, 68-76	301
2002	Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. 2007 , 109, 2279-84	132
2001	Identification of a constitutively active mutant of JAK3 by retroviral expression screening. 2007 , 31, 203-9	20
2000	Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. 2007 , 31, 1077-84	9

1999	Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. 2007 , 31, 1053-62	37
1998	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). 2007 , 31, 737-40	237
1997	The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges. 2007 , 31, 883-6	1
1996	Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera. 2007 , 1, 1605-12	9
1995	Hematopoietic cytokine receptor signaling. 2007 , 26, 6724-37	212
1994	Aberrant cytokine signaling in leukemia. 2007 , 26, 6738-49	69
1993	Erythroid and megakaryocytic transformation. 2007 , 26, 6803-15	43
1992	High-throughput oncogene mutation profiling in human cancer. 2007 , 39, 347-51	847
1991	Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. 2007 , 7, 673-83	438
1990	JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. 2007 , 21, 367-9	15
1989	Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. 2007 , 21, 505-10	72
1988	JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. 2007 , 21, 1097-9	23
1987	JAK2 V617F due to a novel TG --> CT mutation at nucleotides 1848-1849: diagnostic implication. 2007 , 21, 1344-6	11
1986	Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. 2007 , 21, 1218-23	97
1985	Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. 2007 , 21, 1514-20	71
1984	JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases. 2007 , 21, 1843-5	32
1983	TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. 2007 , 21, 1658-68	222
1982	A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. 2007 , 21, 1964-70	37

1981	AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. 2007 , 21, 2199-201	13	
1980	Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 2007 , 21, 1952-9	273	
1979	T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. 2007 , 21, 2433-41	7	
1978	The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. 2007 , 136, 745-51	128	
1977	Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 2007 , 137, 244-7	142	
1976	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. 2007 , 138, 354-8	120	
1975	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. 2007 , 138, 821-2	90	
1974	JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. 2007 , 139, 64-9	22	
1973	The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. 2007 , 29, 71-2	18	
1972	The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. 2007 , 5, 55-61	121	
1971	JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. 2007 , 5, 859-61	57	
1970	Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. 2007 , 5, 708-14	181	
1969	Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. 2007 , 115, 1267-73	2	
1968	A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. 2007 , 172, 107-12	10	
1967	Copy number increase of 1p36.33 and mitochondrial genome amplification in Epstein-Barr virus-transformed lymphoblastoid cell lines. 2007 , 173, 122-30	43	
1966	Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. 2007 , 179, 19-24	8	
1965	FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. <i>Cancer Cell</i> , 2007 , 12, 367-80	24.3	151
1964	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. <i>Cancer Cell</i> , 2007 , 12, 501-13	24.3	154

1963	Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. 2007 , 122, 279-87	24
1962	Polycythemia vera is not initiated by JAK2V617F mutation. 2007 , 35, 32-8	162
1961	In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. 2007 , 35, 587-95	34
1960	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. 2007 , 35, 702-11	147
1959	Imatinib effect on growth and signal transduction in polycythemia vera. 2007 , 35, 931-8	18
1958	Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. 2007 , 35, 1624-32	8
1957	JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. 2007 , 35, 1695-703	30
1956	Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. 2007 , 35, 1633-40	37
1955	Erratum. 2007 , 35, 1476.e1-1476.e11	
1954	Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. 2007 , 35, 1641-6	77
1953	Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera. 2007 , 35, 1647-56	10
1952	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 2007 , 35, 1708-18	63
1951	Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. 2007 , 35, 1668-76	35
1950	Epigenetic control of PRV-1 expression on neutrophils. 2007 , 35, 1677-83	10
1949	Introduction: The seed was planted in Experimental Hematology. 2007 , 35, 1623	
1948	Advances in the understanding and management of myeloproliferative disorders. 2007 , 79, 2-4	1
1947	Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders. 2007 , 79, 5-8	3
1946	Phenotype and genotype in the myeloproliferative disorders. 2007 , 79, 9-12	2

1945	Unanswered questions in polycythaemia vera. 2007 , 79, 18-21	
1944	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. 2007 , 79, 508-15	108
1943	Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 2007 , 25, 165-73	100
1942	Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. 2008 , 6, 203-5	24
1941	The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. 2007 , 85, 338-43	27
1940	The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocytotic": a molecular, histologic, and clinical study. 2007 , 86, 130-6	12
1939	Lineage-specific clonality analysis of chronic myeloproliferative disorders and myelodysplastic syndrome by human androgen receptor assay. 2007 , 13, 114-22	2
1938	[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]. 2007 , 102, 770-7	
1937	Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. 2007 , 86, 239-44	17
1936	Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. 2007 , 86, 245-53	20
1935	Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. 2007 , 86, 355-61	2
1934	Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause. 2007 , 86, 801-3	5
1933	Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. 2007 , 176, 105-9	6
1932	Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. 2007 , 2, 34-42	1
1931	Cytokine signaling to the cell cycle. 2007 , 39, 173-84	17
1930	The treatment of polycythaemia vera: an update in the JAK2 era. 2007 , 2, 13-8	14
1929	JAK2V617F mutation in patients with portal vein thrombosis. 2008 , 53, 2778-83	21
1928	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. 2008 , 87, 269-76	36

1927	The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. 2008 , 87, 1-10	37
1926	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. 2008 , 87, 741-9	39
1925	Chronische Myeloproliferative Erkrankungen (CMPE). 2008 , 3, 59-77	
1924	Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential thrombocythemia. 2008 , 2, 309-313	
1923	Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. 2008 , 52, 103-12	6
1922	JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera. 2008 , 88, 82-87	3
1921	Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. 2008 , 88, 197-201	9
1920	Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation. 2008 , 88, 181-188	6
1919	Phase II open label trial of imatinib in polycythemia rubra vera. 2008 , 88, 489-494	5
1918	[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets]. 2008 , 37, 394-403	
1917	Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies. 2008 , 50, 859-61	6
1916	JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I. 2008 , 51, 689-91	2
1915	Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia. 2008 , 51, 691-3	19
1914	Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. 2008 , 51, 802-5	10
1913	How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe. 2008 , 26, 3-7	0
1912	Familial chronic myeloproliferative disorders: the state of the art. 2008 , 26, 131-8	28
1911	JAK2 V617F mutation is not involved in thromboembolism in IBD. 2008 , 14, 1606-7	7
1910	Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. 2008 , 123, 1586-92	46

1909	Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. 2008 , 47, 729-39	70
1908	Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. 2008 , 47, 884-9	49
1907	Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. 2008 , 83, 491-7	66
1906	A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). 2008 , 32, 421-7	27
1905	Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies. 2008 , 32, 369-77	9
1904	Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines. 2008 , 32, 811-9	6
1903	Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis. 2008 , 26, 1732-42	39
1902	Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 2008 , 26, 1920-30	82
1901	Therapeutic targeting of Janus kinases. 2008 , 223, 132-42	190
1900	Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. 2008 , 22, 1368-76	31
1899	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 2008 , 22, 1299-307	239
1898	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. 2008 , 22, 1320-34	23
1897	New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. 2008 , 22, 1557-66	87
1896	Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. 2008 , 22, 1494-502	84
1895	Cooperating gene mutations in acute myeloid leukemia: a review of the literature. 2008 , 22, 915-31	271
1894	Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). 2008 , 22, 1818-27	27
1893	Systematic genomic screen for tyrosine kinase mutations in CLL. 2008 , 22, 1966-9	27
1892	SOCS2: inhibitor of JAK2V617F-mediated signal transduction. 2008 , 22, 2169-75	34

1891	JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. 2008 , 22, 1813-7	91
1890	BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. 2008 , 22, 1975-89	16
1889	Genetic complexity of myeloproliferative neoplasms. 2008 , 22, 1841-8	73
1888	Aberrant signal transduction pathways in myeloproliferative neoplasms. 2008 , 22, 1828-40	51
1887	Miscreant myeloproliferative disorder stem cells. 2008 , 22, 2011-9	20
1886	Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. 2008 , 22, 905-14	151
1885	A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. 2008 , 22, 965-70	104
1884	Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. 2008 , 21, 826-36	30
1883	JAK kinases overexpression promotes in vitro cell transformation. 2008 , 27, 1511-9	31
1882	Activation of tyrosine kinases by mutation of the gatekeeper threonine. 2008 , 15, 1109-18	311
1881	The history of myeloproliferative disorders: before and after Dameshek. 2008 , 22, 3-13	59
1880	JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. 2008 , 22, 23-30	185
1879	Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. 2008 , 22, 14-22	780
1878	Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. 2008 , 22, 87-95	140
1877	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). 2008 , 22, 740-7	120
1876	HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. 2008 , 22, 578-84	22
1875	Choosing between stem cell therapy and drugs in myelofibrosis. 2008 , 22, 474-86	49
1874	The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. 2008 , 30, 415-9	37

1873	The classification and diagnosis of erythrocytosis. 2008 , 30, 447-59	65
1872	Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. 2008 , 38, 422-6	15
1871	The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. 2008 , 99, 1265-73	52
1870	Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. 2008 , 141, 504-11	51
1869	Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. 2008 , 141, 681-8	54
1868	Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis. 2008 , 142, 986-90	19
1867	The JAK2 V617F mutation and thrombosis. 2008 , 143, 307-20	54
1866	Dasatinib inhibits progenitor cell proliferation from polycythaemia vera. 2008 , 38, 578-84	8
1865	Sweet's syndrome with hematologic disorders: a review and reappraisal. 2008 , 47, 775-82	40
1864	Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. 2008 , 36, 158-71	45
1863	Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. 2008 , 36, 1480-6	68
1862	Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. 2008 , 36, 1471-9	40
1861	Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation. 2008 , 76, 1681-93	28
1860	Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. 2008 , 180, 51-5	26
1859	Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. 2008 , 186, 6-11	5
1858	Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. <i>Cancer Cell</i> , 2008 , 13, 311-20	24.3 301
1857	Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. <i>Cancer Cell</i> , 2008 , 13, 321-30	24.3 113
1856	Deregulation of signaling pathways in acute myeloid leukemia. 2008 , 35, 336-45	117

1855	Canonical and non-canonical JAK-STAT signaling. 2008 , 18, 545-51	200
1854	Mining for JAK-STAT mutations in cancer. 2008 , 33, 122-31	120
1853	Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. 2008 , 111, 3863-6	92
1852	Animal Models of Myelofibrosis. 2008 , 713-723	1
1851	Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. 2008 , Chapter 14, Unit14.10	4
1850	JAK2 and MPL mutations in myeloproliferative neoplasms. 2008 , 119, 218-25	9
1849	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. 2008 , 111, 4922-9	275
1848	Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors. 2008 , 6, 519-29	20
1847	Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. 2008 , 112, 3026-35	104
1846	The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. 2008 , 39, 795-810	50
1845	JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. 2008 , 19, 385-93	137
1844	The JAK kinases: not just another kinase drug discovery target. 2008 , 19, 319-28	70
1843	Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: methodological aspects and applications. 2008 , 42, 203-52	30
1842	Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. 2008 , 40, 160-5	40
1841	Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. 2008 , 41, 284-91	8
1840	Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. 2008 , 10, 1813-48	47
1839	JAK and MPL mutations in myeloid malignancies. 2008 , 49, 388-97	70
1838	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. 2008 , 372, 1484-92	286

- 1837 Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. **2008**, 111, 4809-12 75
- 1836 The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. **2008**, 112, 231-9 137
- 1835 Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. **2008**, 111, 776-84 185
- 1834 A role for JAK2 mutations in myeloproliferative diseases. **2008**, 59, 213-22 71
- 1833 Highlights from the 44th Annual Meeting of the American Society of Clinical Oncology: Chicago, IL; May 30-June 3, 2008. **2008**, 2, 156-162
- 1832 Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. **2008**, 6, 472-5 12
- 1831 Acute Leukemia Arising from the Myeloproliferative Disorders: Challenge and Opportunity. **2008**, 2, 252-256
- 1830 Stat5 as a diagnostic marker for leukemia. **2008**, 8, 73-82 22
- 1829 Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. **2008**, 111, 1686-9 223
- 1828 The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. **2008**, 49, 1907-15 6
- 1827 Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. **2008**, 359, 2778-89 74
- 1826 Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. **2008**, 10, 58-66 51
- 1825 A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. **2008**, 10, 435-41 44
- 1824 Survival and proliferative roles of erythropoietin beyond the erythroid lineage. **2008**, 10, e36 85
- 1823 Prevention of thrombosis in polycythemia vera and essential thrombocythemia. **2008**, 93, 331-5 33
- 1822 Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. **2008**, 283, 12941-8 51
- 1821 Budd-Chiari syndrome and portal venous thrombosis [relevance of the JAK2 mutation as new risk marker]. **2008**, 32, -
- 1820 Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. **2008**, 28, 1792-801 66

1819	WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. 2008 , 14, 788-96	66
1818	LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. 2008 , 7, 1176-84	34
1817	Association between erythropoietin requirements and antihypertensive agents. 2008 , 109, c33-9	4
1816	Mutant molecules of interest in myeloproliferative neoplasms: introduction. 2008 , 119, 192-3	7
1815	Budd-Chiari Syndrom und Portalvenenthrombose [Bedeutung der JAK2-Mutation als neuer Risikomarker / Budd-Chiari syndrome and portal venous thrombosis [Relevance of the JAK2 mutation as a new risk marker. 2008 , 32, 387-396	
1814	JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones. 2008 , 120, 177-81	11
1813	JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors. 2008 , 7, 714-9	10
1812	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 2008 , 93, 41-8	126
1811	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 2008 , 13, 71-6	11
1810	Enhanced histone deacetylase enzyme activity in primary myelofibrosis. 2008 , 49, 2321-7	51
1809	JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 2008 , 93, 34-40	98
1808	Prostate Cancer. 2008 ,	3
1807	Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. 2008 , 283, 5258-66	105
1806	The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. 2008 , 283, 18522-9	10
1805	Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. 2008 , 49, 1784-91	5
1804	A case of essential thrombocythemia in an 8-year-old boy. 2008 , 25, 325-30	3
1803	Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera?. 2008 , 38, 230-2	1
1802	Defining the blueprint of the cancer genome. 2008 , 29, 1087-91	51

1801	Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. 2008 , 205, 751-8	285
1800	Innovative Leukemia and Lymphoma Therapy. 2008 ,	
1799	250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. 2008 , 68, 10349-57	257
1798	Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. 2008 , 7, 2308-18	21
1797	FLT3 inhibitors in acute myeloid leukemia. 2008 , 1, 153-60	8
1796	Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. 2008 , 283, 33569-77	22
1795	Clinical implications of JAK2 mutations in myeloproliferative disorders. 2008 , 63, 93-8	2
1794	The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. 2008 , 93, 1890-3	33
1793	JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. 2008 , 49, 696-9	11
1792	GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. 2008 , 49, 1416-9	9
1791	The role of thrombophilia in splanchnic vein thrombosis. 2008 , 28, 293-301	42
1790	Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. 2008 , 93, 169-72	26
1789	Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. 2008 , 93, 972-6	23
1788	MPL W515L mutation in Chinese patients with myeloproliferative diseases. 2008 , 49, 955-8	9
1787	New advances in the pathogenesis and therapy of essential thrombocythemia. 2008 , 76-82	10
1786	The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?. 2008 , 69-75	27
1785	Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. 2008 , 93, 1635-44	68
1784	The suppressors of cytokine signalling E3 ligases behave as tumour suppressors. 2008 , 36, 464-8	14

1783	Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. 2008 , 111, 5663-71	203
1782	Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. 2008 , 111, 767-75	81
1781	Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. 2008 , 111, 5109-17	172
1780	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. 2008 , 111, 2238-45	62
1779	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. 2008 , 111, 4788-96	77
1778	The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. 2008 , 111, 3751-9	106
1777	Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. 2008 , 111, 4511-22	75
1776	Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. 2008 , 111, 3931-40	355
1775	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. 2008 , 111, 4797-808	166
1774	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. 2008 , 112, 2463-73	92
1773	JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. 2008 , 112, 1402-12	140
1772	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 2008 , 112, 844-7	198
1771	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. 2008 , 112, 2429-38	90
1770	Myeloproliferative disorders. 2008 , 112, 2190-8	235
1769	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. 2008 , 112, 3065-72	439
1768	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. 2008 , 112, 4061-8	119
1767	MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. 2008 , 112, 141-9	324
1766	Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases. 2008 , 2, 209-13	2

1765	Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. 2008 , 19, 459-62	20
1764	New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. 2008 , 15, 121-6	6
1763	Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. 2008 , 32, 928-35	9
1762	An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era. 2008 , 121, 1838-1842	
1761	A mutab JAK2 V617F e as sñdromes mieloproliferativas. 2008 , 30,	3
1760	The role of signal transducers and activators of transcription in colon cancer. 2008 , 13, 2888-99	83
1759	Signaling flux redistribution at toll-like receptor pathway junctions. 2008 , 3, e3430	36
1758	Thrombosis and inflammatory bowel disease-the role of genetic risk factors. 2008 , 14, 4440-4	36
1757	[Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening]. 2009 , 29, 243-8	6
1756	SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. 2009 , 94, 576-80	19
1755	RNAi screen for rapid therapeutic target identification in leukemia patients. 2009 , 106, 8695-700	88
1754	A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. 2009 , 284, 26988-98	33
1753	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. 2009 , 27, 4760-6	133
1752	JAK mutations in high-risk childhood acute lymphoblastic leukemia. 2009 , 106, 9414-8	446
1751	A progenitor cell origin of myeloid malignancies. 2009 , 106, 16616-21	40
1750	Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. 2009 , 132, 713-21	37
1749	The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. 2009 , 284, 12680-90	15
1748	Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. 2009 , 284, 6773-81	58

1747	Molecular diagnosis of myeloproliferative neoplasms. 2009 , 9, 481-92	11
1746	A comprehensive profile of DNA copy number variations in a Korean population: identification of copy number invariant regions among Koreans. 2009 , 41, 618-28	8
1745	Erythropoietins, Erythropoietic Factors, and Erythropoiesis. 2009 ,	10
1744	Bone Marrow. 2009 , 1536-1593	
1743	JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. 2009 , 62, 798-801	41
1742	Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia. 2009 , 69, 262-71	8
1741	HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. 2009 , 18, 929-34	7
1740	Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 2009 , 18, 2068-73	82
1739	Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. 2009 , 8, 26-35	46
1738	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. 2009 , 9, 663-70	25
1737	Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. 2009 , 85, 957-65	58
1736	Philadelphia chromosome-negative chronic myeloproliferative disease. 2009 , 132, 261-80	26
1735	The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. 2009 , 8, 3063-4	14
1734	Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. 2009 , 14, 1-10	4
1733	JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia. 2009 , 64, 429-33	1
1732	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. 2009 , 14, 11-5	22
1731	Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. 2009 , 14, 323-30	22
1730	Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. 2009 , 16, 140-6	13

1729	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. 2009 , 14, 471-9	16
1728	A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia. 2009 , 50, 2089-91	
1727	Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. 2009 , 15, 6891-900	17
1726	Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. 2009 , 27, 6109-16	183
1725	Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. 2009 , 18, 534-40	12
1724	A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients. 2009 , 18, 108-11	4
1723	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. 2009 , 27, 5418-24	317
1722	17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. 2009 , 69, 7302-10	73
1721	Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. 2009 , 37, 37-46	2
1720	Advances in understanding and management of myeloproliferative neoplasms. 2009 , 59, 171-91	136
1719	Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. 2009 , 13, 215-37	40
1718	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. 2009 , 13, 1437-50	18
1717	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. 2009 , 83, 328-33	25
1716	An inhibitor of Janus kinase 2 prevents polycythemia in mice. 2009 , 78, 382-9	18
1715	The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy. 2009 , 31, 200-7	8
1714	Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. 2009 , 37, 416-20	14
1713	Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. 2009 , 37, 1194-200	12
1712	Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. 2009 , 37, 1411-22	35

1711	Derivative (1)t(1;19)(p13;p13) in the setting of myelofibrosis with JAK2 V617F. 2009 , 191, 109-10	1
1710	Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. <i>Cancer Cell</i> , 2009 , 16, 161-71	24-3 65
1709	Janus kinase mutations. 2009 , 36, S6-11	10
1708	Treatment of myelofibrosis in younger patients: to transplant or not?. 2009 , 84, 131-2	1
1707	Prodromal myeloproliferative neoplasms: the 2008 WHO classification. 2010 , 85, 62-9	67
1706	MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes. 2010 , 28, 33-9	13
1705	Imbalance of DNA-dependent protein kinase subunits in polycythemia vera peripheral blood stem cells. 2009 , 124, 600-7	0
1704	Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. 2009 , 115, 1692-700	27
1703	The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. 2009 , 115, 3842-7	180
1702	Genome-wide expression profiling in the Drosophila eye reveals unexpected repression of notch signaling by the JAK/STAT pathway. 2009 , 238, 2235-53	53
1701	Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome. 2009 , 89, 517-522	3
1700	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. 2009 , 90, 58-63	9
1699	Do we know more about essential thrombocythemia because of JAK2V617F?. 2009 , 4, 25-32	1
1698	The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. 2009 , 4, 33-40	60
1697	Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. 2009 , 11, 117-24	23
1696	Essential thrombocythemia: past and present. 2009 , 4, 381-8	21
1695	Pathogenetic and clinical impact of JAK2 mutations in chronic myeloproliferative diseases. 2009 , 2, 89-93	0
1694	Un piñe diagnostique ^viter : ^propos d'un cas d'hyperplaquettose de d'ouverte fortuite. 2009 , 2009, 85-88	1

1693	Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. 2009 , 9, 58	25
1692	Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. 2009 , 7, 1	7
1691	Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia. 2009 , 144, 69-77	16
1690	NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. 2009 , 146, 203-17	21
1689	Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. 2009 , 147, 495-506	55
1688	Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. 2009 , 23, 144-52	12
1687	Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. 2009 , 23, 287-91	27
1686	TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. 2009 , 23, 905-11	351
1685	The complete evaluation of erythrocytosis: congenital and acquired. 2009 , 23, 834-44	83
1684	Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. 2009 , 23, 1577-86	11
1683	Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. 2009 , 22, 476-87	69
1682	The cancer genome. 2009 , 458, 719-24	2272
1681	JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. 2009 , 461, 819-22	480
1680	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. 2009 , 41, 446-9	320
1679	A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. 2009 , 41, 450-4	310
1678	A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. 2009 , 41, 455-9	287
1677	Selectivity and therapeutic inhibition of kinases: to be or not to be?. 2009 , 10, 356-60	182
1676	Kinase drug discovery approaches in chronic myeloproliferative disorders. 2009 , 28, 2305-13	30

1675	SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. 2009 , 28, 3069-80	34
1674	Janus kinases in immune cell signaling. 2009 , 228, 273-87	780
1673	Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. 2009 , 19, 6524-8	23
1672	Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. 2009 , 33, 11-8	35
1671	Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia. 2009 , 33, e207-9	3
1670	Fragment-based discovery of JAK-2 inhibitors. 2009 , 19, 279-82	70
1669	Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. 2009 , 19, 3598-601	39
1668	2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2. 2009 , 19, 6529-33	22
1667	Bioluminometric assay for relative quantification of mutant allele burden: application to the oncogenic somatic point mutation JAK2 V617F. 2009 , 81, 8596-602	7
1666	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. 2009 , 52, 7938-41	36
1665	Thrombopoietin in normal and neoplastic stem cell development. 2009 , 22, 495-9	3
1664	Mechanisms of mutations in myeloproliferative neoplasms. 2009 , 22, 489-94	18
1663	Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications. 2009 , 284, 7-14	7
1662	Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection. 2009 , 401, 148-51	17
1661	Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. 2009 , 408, 39-44	24
1660	Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. 2009 , 15, 114-9	3
1659	Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. 2009 , 43, 304-12	23
1658	The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. 2009 , 9, 870-7	19

1657	Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. 2009 , 387, 219-32	183
1656	Uniparental disomy in cancer. 2009 , 15, 120-8	144
1655	Les syndromes myeloprolifératifs. 2009 , 24, 69-85	0
1654	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. 2009 , 113, 6403-10	309
1653	Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. 2009 , 114, 1628-32	84
1652	Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. 2009 , 9 Suppl 3, S329-39	11
1651	JAK2 inhibitors: A reality? A hope?. 2009 , 9 Suppl 3, S340-5	11
1650	Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. 2009 , 7, 39	40
1649	Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. 2009 , 2, 315-334	24
1648	High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. 2009 , 11, 155-61	42
1647	Therapeutic potential of JAK2 inhibitors. 2009 , 636-42	81
1646	Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. 2009 , 11, 1999-2002	117
1645	Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases. 2009 , 148, 157-79	3
1644	Coagulation in Cancer. 2009 ,	4
1643	Molecular Hematopathology. 2009 , 305-324	1
1642	Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. 2009 , 23, 321-31	65
1641	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. 2009 , 114, 144-7	576
1640	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 2009 , 113, 2895-901	905

1639	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 2009 , 114, 1477-83	168
1638	Treatment options for essential thrombocythemia and polycythemia vera. 2009 , 2, 41-55	5
1637	JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. 2009 , 50, 247-53	28
1636	Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. 2009 , 6, 627-37	102
1635	Primary myelofibrosis: update on definition, pathogenesis, and treatment. 2009 , 60, 233-45	78
1634	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. 2009 , 114, 937-51	3222
1633	Molecular diagnosis of hematopoietic and lymphoid neoplasms. 2009 , 23, 903-33	8
1632	New Insights into the Molecular Pathogenesis of Bcr-Abl ⁻ Negative Myeloproliferative Disorders. 2009 , 3, 33-40	
1631	Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. 2009 , 101, 547-551	11
1630	Specialized Therapeutic Hemapheresis and Phlebotomy. 652-680	
1629	ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. 2009 , 114, 1820-30	38
1628	Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. 2009 , 113, 1522-5	16
1627	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. 2009 , 114, 1842-51	21
1626	Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. 2009 , 113, 5942-50	63
1625	Enrichment of Sca1 ⁺ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. 2009 , 114, 1831-41	9
1624	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. 2009 , 113, 6182-92	321
1623	In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. 2009 , 114, 3018-23	36
1622	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. 2009 , 114, 5473-80	314

1621	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. 2009 , 114, 5024-33	149
1620	Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon- γ 2010 , 432, 255-65	20
1619	Maladie de Vaquez. 2010 , 5, 1-14	
1618	JAK2 kinase inhibitors and myeloproliferative disorders. 2010 , 17, 110-6	18
1617	9. Physiopathology and Treatment of Chronic Myeloproliferative Diseases.. 2010 , 99, 2281-2288	
1616	Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). 2010 , 23, 595-604	5
1615	Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera. 2010 , 115, 667-76	9
1614	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. 2010 , 115, 3109-17	550
1613	Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. 2010 , 115, 3589-97	192
1612	Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. 2010 , 115, 2919-27	63
1611	CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. 2010 , 115, 5232-40	188
1610	Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. 2010 , 115, 1969-75	86
1609	Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. 2010 , 116, 4600-11	19
1608	Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. 2010 , 116, 5961-71	45
1607	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. 2010 , 116, 783-7	129
1606	JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. 2010 , 116, 1528-38	162
1605	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. 2010 , 116, 1205-10; quiz 1387	175
1604	Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. 2010 , 116, 988-92	271

1603	A recessive screen for genes regulating hematopoietic stem cells. 2010 , 116, 5849-58	24
1602	Another Lnk to STAT activation. 2010 , 116, 862-4	3
1601	Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. 2010 , 116, 6023-6	25
1600	miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. 2010 , 116, 437-45	106
1599	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. 2010 , 115, 1131-6	185
1598	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. 2010 , 115, 2901-9	41
1597	Molecular genetics. 90-110	1
1596	Myeloproliferative neoplasms: new translational therapies. 2010 , 77, 667-83	6
1595	A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. 2010 , 89, 691-9	48
1594	The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. 2010 , 89, 979-83	20
1593	Visual screening for JAK2V617F mutation by a disposable dipstick. 2010 , 397, 1911-6	9
1592	A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. 2010 , 91, 136-9	27
1591	Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. 2010 , 91, 174-9	79
1590	Molecular aspects of myeloproliferative neoplasms. 2010 , 91, 165-73	52
1589	The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. 2010 , 91, 189-200	23
1588	Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. 2010 , 92, 320-5	15
1587	New drugs for the treatment of myelofibrosis. 2010 , 5, 15-21	6
1586	Targeted signal transduction therapies in myeloid malignancies. 2010 , 12, 358-65	8

1585	Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. 2010 , 5, 177-84		40
1584	Polycythemia vera. 2010 , 5, 375-84		21
1583	From Vaquez to Dameshek through JAK2 much for polycythemia vera to be feared?. 2010 , 5, 371-3		
1582	JAK2V617F mutation in patients with splanchnic vein thrombosis. 2010 , 55, 1770-7		33
1581	Pseudokinases-remnants of evolution or key allosteric regulators?. 2010 , 20, 772-81		112
1580	Copy number variation at leptin receptor gene locus associated with metabolic traits and the risk of type 2 diabetes mellitus. 2010 , 11, 426		44
1579	JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report. 2010 , 198, 162-5		3
1578	Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. <i>Cancer Cell</i> , 2010 , 17, 584-96	24.3	258
1577	The molecular biology of myeloproliferative disorders. <i>Cancer Cell</i> , 2010 , 18, 7-8	24.3	2
1576	Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. <i>Cancer Cell</i> , 2010 , 18, 524-35	24.3	132
1575	Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. 2010 , 38, 472-80		65
1574	Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia. 2010 , 38, 868-876.e1		4
1573	Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. 2010 , 14, 504-27		45
1572	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. 2010 , 84, 518-24		21
1571	Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders. 2010 , 32, 122-6		8
1570	Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. 2010 , 32, 95-102		5
1569	A large family from Argentina with prekallikrein deficiency due to a compound heterozygosis (T insertion in intron 7 and Asp558Glu in exon 15): prekallikrein Cordoba. 2010 , 85, 363-6		8
1568	Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission. 2010 , 85, 362-3		10

1567	Pain as an emergent issue in thalassemia. 2010 , 85, 367-70	20
1566	A comprehensive, simple molecular assay of common deletions and mutations causing alpha-thalassemia in Southeast Asia and southern China. 2010 , 85, 370-2	2
1565	Primary high-grade ocular adnexal lymphoma: clinicopathological characteristics and prognostic factors of a single-centre series. 2010 , 85, 372-5	3
1564	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. 2010 , 85, 375-7	6
1563	Acute leukemia association with psoriasis: a report on 100 patients from a single center in China. 2010 , 85, 378-9	2
1562	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. 2010 , 85, 380-3	9
1561	JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. 2010 , 85, 383-6	2
1560	Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia. 2010 , 85, 386-9	0
1559	Successful unmanipulated stem cell transplantation from HLA-haploidentical 3-loci-mismatched parents in two children with severe aplastic anemia not responding to immunosuppressive therapy. 2010 , 85, 389-90	4
1558	Somatic mutations and the hierarchy of hematopoiesis. 2010 , 32, 1003-8	18
1557	JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 2010 , 34, 387-9	12
1556	Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. 2010 , 34, 1674-6	19
1555	Thrombohemorrhagic complications of myeloproliferative disorders. 2010 , 24, 227-32	39
1554	A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. 2010 , 20, 153-6	39
1553	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. 2010 , 20, 1724-7	17
1552	The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead. 2010 , 20, 7421-5	21
1551	Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology. 2010 , 11, 54	11
1550	Our changing view of the genomic landscape of cancer. 2010 , 220, 231-43	64

1549	Targeted therapy in haematological malignancies. 2010 , 220, 404-18	26
1548	Haemostasis and thrombosis in liver disease. 2010 , 148, 507-21	81
1547	Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. 2010 , 149, 250-7	82
1546	AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. 2010 , 150, 46-57	37
1545	JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. 2010 , 150, 334-44	36
1544	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 2010 , 24, 1302-9	266
1543	Genomic profiling of high-risk acute lymphoblastic leukemia. 2010 , 24, 1676-85	46
1542	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. 2010 , 24, 1128-38	435
1541	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. 2010 , 24, 1290-8	120
1540	Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification. 2010 , 32, 461-76	42
1539	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96	890
1538	Mutational status of myeloproliferative neoplasms. 2010 , 20, 61-76	12
1537	JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. 2010 , 5, e11157	68
1536	Homeostatic and pathogenic extramedullary hematopoiesis. 2010 , 1, 13-9	130
1535	Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. 2010 , 219	
1534	JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. 2010 , 45, 46-50	10
1533	Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. 2010 , 9, 1945-55	91
1532	Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. 2010 , 133, 942-8	22

1531	beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload. 2010 , 2010, 938640	51
1530	Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?. 2010 , 124, 49-56	12
1529	Enhanced platelet adhesion in essential thrombocythemia after in vitro activation. 2010 , 27, 82-90	
1528	Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. 2010 , 16, 143-55	179
1527	A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. 2010 , 1, 331-45	25
1526	Activation of JAK2-V617F by components of heterodimeric cytokine receptors. 2010 , 285, 16651-63	24
1525	Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. 2010 , 3, 23-33	2
1524	Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. 2010 , 28, 2253-8	113
1523	Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. 2010 , 1, 979-93	139
1522	Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. 2010 , 70, 447-52	243
1521	Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. 2010 , 5, 521-30	9
1520	Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. 2010 , 285, 31399-407	11
1519	STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. 2010 , 285, 5296-307	51
1518	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. 2010 , 16, 755-63	69
1517	[Molecular markers in hematology and oncology]. 2010 , 99, 1143-52	2
1516	Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. 2010 , 3, 3478-3493	3
1515	The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. 2010 , 45, 1587-93	57
1514	Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. 2010 , 16, 1988-96	36

1513	Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. 2010 , 9, 1051-6	11
1512	The molecular pathogenesis of myelodysplastic syndromes. 2010 , 10, 309-19	32
1511	The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. 2010 , 17, 4551-8	31
1510	Heritability of hematologic malignancies: from pedigrees to genomics. 2010 , 24, 939-72	9
1509	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. 2010 , 51, 576-82	8
1508	Hepatology. 2010 , 218-226	
1507	MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. 2010 , 20, 784-93	284
1506	Chronic Myeloproliferative Neoplasms. 2010 , 209-232	
1505	Portal vein thrombosis, revisited. 2010 , 42, 163-70	97
1504	Cytogenetics and genetics of human cancer: methods and accomplishments. 2010 , 203, 102-26	28
1503	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. 2010 , 10, 285-9	71
1502	The constitutive activation of Jak2-V617F is mediated by a β -stacking mechanism involving phenylalanines 595 and 617. 2010 , 49, 9972-84	31
1501	Molecular basis and clonal evolution of myeloproliferative neoplasms. 2010 , 95, 526-9	10
1500	Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. 2010 , 28, 3858-65	257
1499	Janus Kinase 2 (JAK2) Inhibitors for the Treatment of Myeloproliferative Neoplasm (MPN). 2010 , 210-227	2
1498	Myeloproliferative Neoplasms. 2010 , 177-192	2
1497	JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. 2010 , 3, 323-37	65
1496	Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1. 2010 , 291, 246-55	19

1495	Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. 2010 , 51, 67-72	10
1494	JAK2V617F/STAT5 signaling pathway promotes cell proliferation through activation of Pituitary Tumor Transforming Gene 1 expression. 2010 , 398, 707-12	9
1493	Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. 2010 , 411, 2097-100	22
1492	Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. 2010 , 126, 238-42	49
1491	Characterization of a dominant-active STAT that promotes tumorigenesis in Drosophila. 2010 , 344, 621-36	43
1490	JAK2 gene mutation: impact on pathogenesis, classification, and management of myeloproliferative neoplasms. 2010 , 7, 109-114	2
1489	Megakaryopoiesis. 2010 , 47, 212-9	83
1488	Cytokine Receptor Signaling. 2010 , 451-466	1
1487	Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. 2010 , 12, 278-82	16
1486	Development of a reliable PCR-RFLP assay for investigation of the JAK2 rs10974944 SNP, which might predispose to the acquisition of somatic mutation JAK2(V617F). 2010 , 123, 84-7	12
1485	Essential thrombocythaemia and its neurological complications. 2010 , 10, 195-201	5
1484	Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. 2010 , 303, 2513-8	15
1483	Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. 2010 , 12, 58-64	17
1482	A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. 2010 , 12, 512-9	24
1481	Cancer Gene Profiling. 2010 ,	1
1480	Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. 2010 ,	1
1479	Multi-pathway cellular analysis of compound selectivity. 2010 , 6, 1834-43	16
1478	Molecular pathology of myeloproliferative neoplasms. 2010 , 133, 602-15	21

1477	Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. 2010 , 116, 3572-81	98
1476	Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine. 2010 , 14, 185-90	4
1475	JAK-mutant myeloproliferative neoplasms. 2012 , 355, 119-33	17
1474	Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia. 2011 , 13, 263-70	23
1473	Diagnostic Molecular Pathology in Practice. 2011 ,	1
1472	Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. 2011 , 13, 558-64	14
1471	Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments. 2011 , 50, 7774-86	6
1470	The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. 2011 , 51, 1644-54	110
1469	JAK2 inhibitors: are they the solution?. 2011 , 11 Suppl 1, S28-36	5
1468	Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. 2011 , 1, e40	30
1467	Normal and malignant megakaryopoiesis. 2011 , 13, e32	17
1466	Genomics and the continuum of cancer care. 2011 , 364, 340-50	247
1465	Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxo-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacos-1(25),2(26),3,5,8,10,12(11,14)heptacosane (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. 2011 , 54, 4638-58	114
1464	Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. 2011 , 54, 7334-49	60
1463	PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. 2011 , 15, 53-62	17
1462	Virtual Screening on Homology Models. 2011 , 381-410	3
1461	Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. 2011 , 118, 177-81	55
1460	Myeloproliferative disorders in pregnancy. 2011 , 25, 261-75, vii	22

1459	Molecular studies in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. 2011 , 321-331	
1458	JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. 2011 , 23, 17-21	8
1457	JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 2011 , 2, 21-32	63
1456	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. 2011 , 1, e7	11
1455	New JAK2 inhibitors for myeloproliferative neoplasms. 2011 , 20, 961-72	18
1454	Absolute quantification of the alleles in somatic point mutations by bioluminometric methods based on competitive polymerase chain reaction in the presence of a locked nucleic acid blocker or an allele-specific primer. 2011 , 83, 6545-51	5
1453	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. 2011 , 7, 1035-43	28
1452	Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. 2011 , 54, 8440-50	37
1451	Hematopathology. 2011 ,	
1450	Evaluation of the bioactive and total transforming growth factor β levels in primary myelofibrosis. 2011 , 53, 100-6	22
1449	Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. 2011 , 47, 67-71	12
1448	Exploring the genomes of cancer cells: progress and promise. 2011 , 331, 1553-8	488
1447	A potential role of ruxolitinib in leukemia. 2011 , 20, 1159-66	12
1446	[Utility of the bone marrow biopsy in the diagnosis of essential thrombocythemia]. 2011 , 40, e507-15	
1445	JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. 2011 , 59, e89-92	6
1444	Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis--a concise review. 2011 , 127, 505-12	33
1443	Targeting miR-375 in gastric cancer. 2011 , 15, 961-72	24
1442	Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. 2011 , 52, 1178-87	11

1441	Genetics of the Myeloproliferative Neoplasms. 2011 , 39-68	
1440	The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. 2011 , 25, 1891-9	60
1439	The HIF pathway and erythrocytosis. 2011 , 6, 165-92	128
1438	BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. 2011 , 11 Suppl 1, S37-45	19
1437	Molecular Pathology of Myeloproliferative Neoplasms. 2011 , 215-253	
1436	Myelodysplastic/myeloproliferative neoplasms. 2011 , 28, 283-97	15
1435	. 2011 ,	26
1434	JAK2 (janus kinase 2). 2011 ,	
1433	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. 2011 ,	1
1432	Myeloproliferative neoplasms. 217-244	
1431	Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients. 2011 , 47, 873-886	12
1430	Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. 2011 , 23, 609-16	29
1429	Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. 2011 , 2011, 536062	60
1428	Involvement of phosphatases in proliferation, maturation, and hemoglobinization of developing erythroid cells. 2011 , 2011, 860985	6
1427	Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. 2011 , 6, e18522	28
1426	Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. 2011 , 6, e18552	65
1425	Targeting myeloproliferative neoplasms with JAK inhibitors. 2011 , 18, 105-10	30
1424	Genetics of the myeloproliferative neoplasms. 2011 , 18, 117-23	43

1423	The use of structural biology in Janus kinase targeted drug discovery. 2011 , 12, 546-55	42
1422	Special edition myeloproliferative neoplasia - disease pathogenesis and treatment options. 2011 , 11, 1-2	1
1421	The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. 2011 , 96, 1613-8	11
1420	A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. 2011 , 118, 156-66	121
1419	R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. 2011 , 117, 6866-75	21
1418	JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. 2011 , 117, 4056-64	91
1417	The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. 2011 , 118, 425-36	33
1416	3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. 2011 , 117, 5860-9	79
1415	Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. 2011 , 118, 1610-21	39
1414	Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- β . 2011 , 118, 2170-3	55
1413	EZH2 mutational status predicts poor survival in myelofibrosis. 2011 , 118, 5227-34	204
1412	A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia. 2011 , 50, 2649-52	9
1411	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 2011 , 96, 367-74	60
1410	Venous thromboembolic disease. 2011 , 9, 714-77	57
1409	JAK2 mutations in Asian patients with essential thrombocythaemia. 2011 , 41, 191-6	6
1408	Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. 2011 , 41, 408-15	1
1407	Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. 2011 , 33, 1087-103	55
1406	Advances in understanding the pathogenesis of familial thrombocythaemia. 2011 , 152, 701-12	32

1405	Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. 2011 , 152, 677-87	119
1404	LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. 2011 , 13, 13-21	101
1403	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. 2011 , 17, 304-12	77
1402	Cancer genomics: from discovery science to personalized medicine. 2011 , 17, 297-303	415
1401	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. 2011 , 10, 127-40	229
1400	Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. 2011 , 30, 3502-12	44
1399	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. 2011 , 25, 218-25	105
1398	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. 2011 , 25, 1365-8	19
1397	JAK2V617F mutation in patients with thrombosis: to screen or not to screen?. 2011 , 33, 117-24	31
1396	The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. 2011 , 86, 148-55	49
1395	Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. 2011 , 87, 54-60	49
1394	Versatility of PRMT5-induced methylation in growth control and development. 2011 , 36, 633-41	175
1393	Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. 2011 , 35, 1632-6	13
1392	Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?. 2011 , 38, 196-214	19
1391	In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. 2011 , 39, 14-25	6
1390	Identification of JAK2 mutations in canine primary polycythemia. 2011 , 39, 542-5	15
1389	Differential biological activity of disease-associated JAK2 mutants. 2011 , 585, 1007-13	19
1388	Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. 2011 , 585, 1884-90	26

1387	JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. <i>Cancer Cell</i> , 2011 , 19, 283-94	24.3	203
1386	Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. 2011 , 23, 849-56		25
1385	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. 2011 , 23, 2076-85		34
1384	Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. 2011 , 54, 262-76		110
1383	Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. 2011 , 1, 297-311		40
1382	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. 2011 , 29, 573-82		238
1381	Pathogenesis and consequences of uniparental disomy in cancer. 2011 , 17, 3913-23		71
1380	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 2011 , 118, 167-76		129
1379	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. 2011 , 117, e198-206		126
1378	New mutations and pathogenesis of myeloproliferative neoplasms. 2011 , 118, 1723-35		316
1377	Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. 2011 , 29, 818-26		17
1376	Mouse models of diseases of megakaryocyte and platelet homeostasis. 2011 , 22, 449-65		1
1375	The role of HLA-G in immunity and hematopoiesis. 2011 , 68, 353-68		52
1374	Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. 2011 , 19, 968-77		35
1373	Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera. 2011 , 28, 1555-8		10
1372	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. 2011 , 2, 197-212		29
1371	Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. 2011 , 11, 24		18
1370	Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. 2011 , 4, 4		7

1369	Development of a highly sensitive method for detection of JAK2V617F. 2011 , 4, 40	11
1368	Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. 2011 , 12, 443	30
1367	The JAK2 exon 12 mutations: a comprehensive review. 2011 , 86, 668-76	115
1366	Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. 2011 , 86, 785-7	8
1365	Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. 2011 , 86, 790-2	8
1364	Sideroblastic anemia, iron overload, and ALAS2 R452S in African-American males: phenotype and genotype features of five unrelated patients. 2011 , 86, 787-9	2
1363	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. 2011 , 86, 796-800	34
1362	An evaluation of concurrent G6PD (A-) deficiency and sickle cell trait in Malian populations of children with severe or uncomplicated <i>P. falciparum</i> malaria. 2011 , 86, 795-6	9
1361	Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. 2011 , 86, 792-4	2
1360	Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. 2011 , 86, 800-3	
1359	Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. 2011 , 86, 804-6	23
1358	Changing patterns of splenectomy in transfusion-dependent thalassemia patients. 2011 , 86, 808-10	23
1357	Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. 2011 , 86, 806-8	32
1356	Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. 2011 , 86, 974-9	31
1355	Experimental therapeutics for patients with myeloproliferative neoplasias. 2011 , 117, 662-76	15
1354	Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis. 2011 , 25, 300-4	5
1353	JAK2 inhibitors: what's the true therapeutic potential?. 2011 , 25, 53-63	61
1352	Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. 2011 , 21, 1425-8	17

1351	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. 2011 , 21, 2958-61	14
1350	Shooting the messenger: targeting signal transduction pathways in leukemia and related disorders. 2011 , 78, 33-44	8
1349	Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. 2011 , 35, 608-13	24
1348	Genetic alterations targeting lymphoid development in acute lymphoblastic leukemia. 2011 , 94, 171-96	8
1347	Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. 2011 , 1, e29	35
1346	The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction. 2011 , 286, 5034-42	12
1345	Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes. 2011 , 52, 2023-6	7
1344	Update on JAK2 Inhibitors in Myeloproliferative Neoplasm. 2011 , 2, 61-71	2
1343	How I treat splenomegaly in myelofibrosis. 2011 , 1, e37	18
1342	A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. 2011 , 18, 4659-73	7
1341	Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders. 2011 , 15, 17-21	9
1340	Janus kinase 2 inhibitors in myeloproliferative disorders. 2011 , 20, 41-59	14
1339	JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?. 2011 , 2, 203-11	2
1338	Acquired erythrocytosis upon treatment with infliximab for ankylosing spondylitis. 2011 , 38, 581-3	1
1337	Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. 2011 , 71, 3831-40	70
1336	A new frontier in personalized cancer therapy: mapping molecular changes. 2011 , 7, 873-94	12
1335	Making sense of cancer genomic data. 2011 , 25, 534-55	260
1334	Erythrocytosis and polycythemia. 2011 , 333-345	

1333	Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report. 2011 , 2011, 404057	1
1332	When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms. 2011 , 2, 11-9	7
1331	Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. 2011 , 17, 7347-58	79
1330	Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. 2011 , 64, 75-82	24
1329	Phosphoproteins and the dawn of functional phenotyping. 2011 , 78, 115-21	7
1328	Thrombopoietin and hematopoietic stem cells. 2011 , 10, 1582-9	88
1327	Mouse models of myeloproliferative neoplasms: JAK of all grades. 2011 , 4, 311-7	70
1326	JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. 2011 , 1, 1681-1693	1
1325	Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. 2011 , 11, 20-30	10
1324	The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. 2011 , 286, 4280-91	12
1323	FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. 2011 , 71, 2901-15	39
1322	Telomere Dysfunction in Human Genetic Disease. 2011 ,	
1321	Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition. 2011 , 9, 311-8	5
1320	Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. 2011 , 17, 845-53	60
1319	Drosophila: a model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias. 2011 , 4, 439-45	55
1318	Direct effects of type I interferons on cells of the immune system. 2011 , 17, 2619-27	316
1317	Management of essential thrombocythemia. 2011 , 2011, 215-21	33
1316	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. 2012 , 3, 341-54	36

1315	Janus activated kinase inhibition in myelofibrosis. 2012 , 49, 260-5	
1314	The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. 2012 , 1, 184-90	28
1313	Janus kinase 3: the controller and the controlled. 2012 , 44, 187-96	21
1312	STAT signaling in the pathogenesis and treatment of myeloid malignancies. 2012 , 1, 55-64	40
1311	Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia. 2012 , 32, 3681-94	28
1310	Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. 2012 , 30, 2995-3001	141
1309	New generation small-molecule inhibitors in myeloproliferative neoplasms. 2012 , 19, 117-23	20
1308	Promise and pitfalls of kinase inhibitors for rheumatoid arthritis. 2012 , 7, 413-423	
1307	Pathology consultation on myeloproliferative neoplasms. 2012 , 138, 12-9	3
1306	STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. 2012 , 1, 13-22	18
1305	Regulation of p27 (Kip1) by mitogen-induced tyrosine phosphorylation. 2012 , 11, 1910-7	39
1304	JAK2 inhibition for the treatment of hematologic and solid malignancies. 2012 , 21, 637-55	21
1303	Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2. 2012 , 11, 3611-26	11
1302	JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?. 2012 , 12, 1098-109	18
1301	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. 2012 , 25, 65-74	30
1300	Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. 2012 , 53, 2479-86	9
1299	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. 2012 , 120, 1202-9	179
1298	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. 2012 , 8, 575-93	3

1297	JAK2 inhibitors in the treatment of myeloproliferative neoplasms. 2012 , 21, 1755-74	14
1296	EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. 2012 , 26, 720-7	15
1295	Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. 2012 , 2, e63	31
1294	Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. 2012 , 109, 6668-73	23
1293	Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. 2012 , 26, 894-906	39
1292	Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. 2012 , 109, 19368-73	95
1291	Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. 2012 , 209, 259-73	129
1290	Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays. 2012 , 10, 212-7	2
1289	Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. 2012 , 18, 2754-67	46
1288	Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies. 2012 , 5, 779-801	11
1287	JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms. 2012 , 2012, 535709	4
1286	Current and emerging therapies in primary myelofibrosis. 2012 , 12, 6-20	1
1285	Cell biology: a key driver of therapeutic innovation. 2012 , 199, 571-5	1
1284	Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. 2012 , 19, 4399-413	71
1283	Evaluation of the presence of hereditary and acquired thrombophilias in Brazilian children and adolescents with diagnoses of portal vein thrombosis. 2012 , 55, 599-604	17
1282	Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme. 2012 , 10,	0
1281	The different faces of Janus kinase inhibition. 2012 , 97, 475	
1280	Chronic myeloproliferative disorders. 444-502	3

1279	Essential thrombocythemia: new advances in an old disease. 2012 , 2, 603-614	1
1278	Efficacy of vorinostat in a murine model of polycythemia vera. 2012 , 119, 3779-89	40
1277	Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. 2012 , 647-658	1
1276	The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. 2012 , 119, 1190-9	30
1275	Critical requirement for Stat5 in a mouse model of polycythemia vera. 2012 , 119, 3539-49	94
1274	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. 2012 , 119, 4625-35	37
1273	Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. 2012 , 120, 1888-98	4
1272	Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. 2012 , 120, 166-72	50
1271	Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. 2012 , 120, 2853-63	36
1270	Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. 2012 , 120, 1367-79	85
1269	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. 2012 , 120, 4945-51	105
1268	Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice. 2012 , 97, 1389-93	4
1267	Ruxolitinib for myelofibrosis. 2012 , 2, 1023-1031	
1266	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. 2012 , 366, 787-98	1232
1265	Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. 2012 , 159, 172-81	37
1264	Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. 2012 , 25, 815-27	17
1263	Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. 2012 , 26, 1053-64	23
1262	Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. 2012 , 36, 1124-7	61

1261	Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. 2012 , 55, 10090-107	64
1260	[Myeloproliferative disorders "Philadelphia negative" and JAK2V617F mutation: study of 15 cases in Togo]. 2012 , 70, 591-4	
1259	The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. 2012 , 34, 388-96	17
1258	Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. 2012 , 24, 2024-34	13
1257	Role of additional novel therapies in myeloproliferative neoplasms. 2012 , 26, 959-80	6
1256	Small molecular therapies for rheumatoid arthritis: where do we stand?. 2012 , 21, 23-31	6
1255	Targeting JAK2 in the therapy of myeloproliferative neoplasms. 2012 , 16, 313-24	16
1254	How I treat polycythemia vera. 2012 , 120, 275-84	64
1253	Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. 2012 , 5, 631-41	3
1252	The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. 2012 , 52, 809-18	70
1251	Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. 2012 , 18, 3008-14	128
1250	Regulation of JAKs: Insights Gleaned from the Functional Protein Domains. 2012 , 5-25	
1249	Nuclear Functions of the Janus Kinases. 2012 , 27-46	
1248	Activation of Janus Kinases During Tumorigenesis. 2012 , 259-288	2
1247	The Role of Janus Kinases in Hematopoietic Malignancies. 2012 , 239-258	1
1246	Impact of STAT5 on Normal Tissue Development and Cancer. 2012 , 335-351	
1245	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. 2012 , 120, 2704-7	81
1244	Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. 2012 , 2, 512-523	91

1243	SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). 2012 , 120, 3080-8	234
1242	Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis. 2012 , 111, 34-40	4
1241	Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. 2012 , 36, 239-50	185
1240	Janus kinase deregulation in leukemia and lymphoma. 2012 , 36, 529-41	99
1239	Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm. 2012 , 205, 295-303	6
1238	Myeloproliferative neoplasms. 2012 , 58, 177-94	7
1237	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 2012 , 87, 1010-6	52
1236	Myeloid malignancies: mutations, models and management. 2012 , 12, 304	101
1235	Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. 2012 , 5, 43	24
1234	Genotype-phenotype interactions in the myeloproliferative neoplasms. 2012 , 26, 993-1015	5
1233	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. 2012 , 19, 754-9	162
1232	Biology and significance of the JAK/STAT signalling pathways. 2012 , 30, 88-106	277
1231	CHAPTER 8:Janus Kinases □Just Another Kinase or a Paradigm Shift for the Treatment of Autoimmune Disease?. 2012 , 211-254	
1230	Why does my patient have erythrocytosis?. 2012 , 26, 267-83, vii-viii	12
1229	Why does my patient have thrombocytosis?. 2012 , 26, 285-301, viii	22
1228	Myelofibrosis 2012: it's complicated. 2012 , 3, 131-46	4
1227	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). 2012 , 120, 5128-33; quiz 5252	340
1226	JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. 2012 , 31, 1323-33	76

1225	Role of germline genetic factors in MPN pathogenesis. 2012 , 26, 1037-51	14
1224	The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. 2012 , 181, 858-65	6
1223	Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. 2012 , 49, 170-6	36
1222	Front-line therapy in polycythemia vera and essential thrombocythemia. 2012 , 26, 205-11	48
1221	Chronic neutrophilic leukemia with JAK2 gene mutation. 2012 , 9, 127-131	8
1220	JAK2 the future: therapeutic strategies for JAK-dependent malignancies. 2012 , 33, 574-82	56
1219	Investigation of the influence of body weight index to the result of therapeutic erythrocytapheresis in patients with polycythemia vera. 2012 , 47, 295-9	5
1218	Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. 2012 , 6, 484-93	61
1217	Inhibition of Janus kinase 2 by cyclometalated rhodium complexes. 2012 , 3, 696	29
1216	Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. 2012 , 26, 563-71	44
1215	Development of Amplification-Based Molecular Genetic Testing in Hematology. 2012 , 155-167	
1214	Function of JAKs and STATs in Lymphocytes: Bench to Bedside. 2012 , 205-237	
1213	The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. 2012 , 29, 2379-84	10
1212	SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. 2012 , 22, 7653-8	23
1211	The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. 2012 , 96, 611-6	12
1210	Molecular Genetics and Personalized Medicine. 2012 ,	1
1209	Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. 2012 , 91, 1555-62	8
1208	New pieces of a puzzle: the current biological picture of MPN. 2012 , 1826, 415-22	5

1207	Therapy with JAK2 inhibitors for myeloproliferative neoplasms. 2012 , 26, 1083-99	16
1206	Disordered signaling in myeloproliferative neoplasms. 2012 , 26, 1017-35	7
1205	Disorders of Thrombosis and Hemostasis in Pregnancy. 2012 ,	8
1204	JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. 2012 , 16, 802-5	7
1203	Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. 2012 , 16, 269-83	13
1202	Sequential occurrence of thrombotic thrombocytopenic purpura, essential thrombocythemia, and idiopathic thrombocytopenic purpura in a 42-year-old African-American woman: a case report and review of the literature. 2012 , 6, 93	6
1201	Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera. 2012 , 7, e37207	13
1200	Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease. 2012 , 7, e38362	5
1199	A rare cause of cardiac tamponade. 2012 , 67, 719-21	2
1198	Cross-Regulation of JAK-STAT Signaling: Implications for Approaches to Combat Chronic Inflammatory Diseases and Cancers. 2012 ,	
1197	JAK Kinases in Health and Disease: An Update. 2012 , 6, 232-44	69
1196	Activating Mutations and Targeted Therapy in Cancer. 2012 ,	3
1195	Insights into the molecular genetics of myeloproliferative neoplasms. 2012 , 411-8	4
1194	The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. 2012 , 58, 91-100	11
1193	Recent developments in myelofibrosis. 2012 , 125	2
1192	The Therapeutic Applications of Janus Kinase Inhibition in Psoriasis. 2012 , 18a, 118-125	
1191	Janus kinase inhibitors: jackpot or potluck?. 2012 , 6, e13	
1190	Ruxolitinib for the treatment of myelofibrosis: its clinical potential. 2012 , 8, 95-103	29

1189	Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. 2012 , 5, 119-25	15
1188	The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. 2012 , 13, 6	11
1187	Targeting the interleukin-6/Jak/stat pathway in human malignancies. 2012 , 30, 1005-14	395
1186	Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. 2012 , 59, 530-5	13
1185	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 610-9	37
1184	JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?. 2012 , 87, 1028-36	19
1183	TET2 is essential for survival and hematopoietic stem cell homeostasis. 2012 , 26, 2216-23	64
1182	Budd-Chiari syndrome and venoocclusive disease. 2012 , 1188-1222.e6	
1181	A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L. 2012 , 367, 125-40	4
1180	Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. 2012 , 39, 8663-7	11
1179	JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis. 2012 , 24, 72-6	7
1178	The role of pseudokinases in cancer. 2012 , 24, 1173-84	27
1177	A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. 2012 , 40, 22-34	
1176	Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. 2012 , 22, 1402-7	8
1175	Management of haematological malignancy in pregnancy. 2012 , 26, 149-60	9
1174	Mutational determinants of epigenetic instability in myeloid malignancies. 2012 , 39, 80-96	2
1173	Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility. 2012 , 34, 248-53	8
1172	Thrombocytosis: a retrospective study of 165 dogs. 2012 , 41, 216-22	26

1171	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. 2012 , 36, 485-7	5
1170	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. 2012 , 157, 426-37	18
1169	Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression. 2012 , 62, 433-7	8
1168	Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. 2012 , 5, 2	28
1167	Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. 2012 , 7, 34-42	7
1166	Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?. 2012 , 7, 78-86	28
1165	Role of TET2 mutations in myeloproliferative neoplasms. 2012 , 7, 57-64	26
1164	Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. 2012 , 7, 50-6	19
1163	Budd-Chiari syndrome revisited: 38'years' experience with surgical portal decompression. 2012 , 16, 286-300; discussion 300	42
1162	Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. 2013 , 38, 44-6	16
1161	Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. 2013 , 6, 11	15
1160	A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. 2013 , 162, 498-508	58
1159	Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. 2013 , 17, 429-37	7
1158	P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. 2013 , 76, 9-16	33
1157	AKT is a therapeutic target in myeloproliferative neoplasms. 2013 , 27, 1882-90	51
1156	Somatic SETBP1 mutations in myeloid malignancies. 2013 , 45, 942-6	178
1155	Hematological Malignancies. 2013 ,	6
1154	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. 2013 , 13, 348	3

1153	Quantitative threefold allele-specific PCR (QuantAS-PCR) for highly sensitive JAK2 V617F mutant allele detection. 2013 , 13, 206	11
1152	Lymphoid malignancies: Another face to the Janus kinases. 2013 , 27, 63-70	12
1151	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1
1150	Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy. 2013 , 8, 116-22	8
1149	Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. 2013 , 97, 695-702	28
1148	A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. 2013 , 97, 351-9	12
1147	JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients. 2013 , 97, 409-13	10
1146	Therapy with JAK 1/2 inhibitors for myelofibrosis. 2013 , 6, 109-113	
1145	Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. 2013 , 5, 1047-59	98
1144	Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. 2013 , 54, 2226-30	37
1143	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α . 2013 , 122, 893-901	156
1142	Practical management of patients with myelofibrosis receiving ruxolitinib. 2013 , 6, 511-23	24
1141	[Treatment of essential thrombocythemia]. 2013 , 141, 260-4	3
1140	Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. 2013 , 20, 1221-3	69
1139	JAK-STAT Signalling. 2013 ,	1
1138	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPN-EuroNet (COST action BM0902) study. 2013 , 27, 2032-9	78
1137	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. 2013 , 88, 967-74	22
1136	Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. 2013 , 369, 2391-2405	1262

1135	Another piece of the myeloproliferative neoplasms puzzle. 2013 , 369, 2451-2	10
1134	Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. 2013 , 2, 24	16
1133	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. 2013 , 12, 142	17
1132	Preclinical models for drug selection in myeloproliferative neoplasms. 2013 , 8, 317-24	2
1131	Genetic basis of MPN: Beyond JAK2-V617F. 2013 , 8, 299-306	15
1130	[Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis]. 2013 , 34 Suppl 2, 201-9	
1129	Myelofibrosis: an update on current pharmacotherapy and future directions. 2013 , 14, 873-84	10
1128	Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. 2013 , 6, 429-39	8
1127	Splanchnic vein thrombosis in myeloproliferative neoplasms. 2013 , 162, 730-47	45
1126	Identification of steroid-sensitive gene-1/Ccdc80 as a JAK2-binding protein. 2013 , 27, 619-34	6
1125	Anagrelide hydrochloride for essential thrombocythemia. 2013 , 1, 1049-1062	
1124	Addition of β -mercaptoethanol is a prerequisite for high-quality RNA isolation using QIAasympyphony technology as demonstrated by detection of molecular aberrations in hematologic malignancies. 2013 , 17, 475-80	3
1123	Pharmacotherapy of polycythemia vera. 2013 , 1, 977-985	
1122	JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. 2013 , 122, 2167-75	72
1121	Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. 2013 , 41, 1048-54	10
1120	Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. 2013 , 22, 1603-11	8
1119	The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms. 2013 , 54, 21-6	11
1118	JAKs and STATs in immunity, immunodeficiency, and cancer. 2013 , 368, 161-70	545

1117	Methods for detecting mutations in the human JAK2 gene. 2013 , 967, 115-31	2
1116	The Pathogenesis, Diagnosis, and Treatment of Polycythaemia Vera. 2013 , 135-153	
1115	Therapeutic dilemmas in the treatment of acute coronary syndrome as manifestation of essential thrombocythaemia. 2013 , 8, 168-171	1
1114	Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. 2013 , 37, 911-6	29
1113	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. 2013 , 50, 190-5	19
1112	The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis. 2013 , 132, e86-93	2
1111	Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide. 2013 , 37, 917-21	19
1110	Emerging drugs for polycythemia vera. 2013 , 18, 393-404	7
1109	Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs. 2013 , 25, 2115-24	6
1108	Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. 2013 , 15, 733-44	34
1107	Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. 2013 , 30, 398	
1106	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. 2013 , 19, 1933-40	205
1105	Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. 2013 , 23, 449-501	42
1104	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. 2013 , 160, 25-34	68
1103	JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. 2013 , 160, 177-87	30
1102	Inheritance of the chronic myeloproliferative neoplasms. A systematic review. 2013 , 83, 99-107	15
1101	Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. 2013 , 1, 5	118
1100	Macrophages support pathological erythropoiesis in polycythemia vera and β -thalassemia. 2013 , 19, 437-45	161

1099	Signal transduction in the chronic leukemias: implications for targeted therapies. 2013 , 8, 71-80	21
1098	Thrombocytosis and Essential Thrombocythemia. 2013 , 999-1017	
1097	Investigational Janus kinase inhibitors. 2013 , 22, 687-99	38
1096	Genetic and epigenetic alterations of myeloproliferative disorders. 2013 , 97, 183-97	47
1095	JAK/STAT signaling in hematological malignancies. 2013 , 32, 2601-13	346
1094	Lessons from the cancer genome. 2013 , 153, 17-37	912
1093	A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. 2013 , 27, 2187-95	116
1092	MicroRNAs in myeloproliferative neoplasms. 2013 , 161, 471-83	28
1091	Laboratory detection of JAK2V617F in human myeloproliferative neoplasms. 2013 , 999, 41-57	2
1090	Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. 2013 , 779, 179-96	14
1089	In vitro JAK kinase activity and inhibition assays. 2013 , 967, 39-55	15
1088	Genetically informed therapy in leukemia. 2013 , 368, 1838-9	1
1087	Thrombocythémie essentielle. 2013 , 8, 1-11	
1086	The role of cytokines in the initiation and progression of myelofibrosis. 2013 , 24, 133-45	98
1085	Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. 2013 , 8, e57856	10
1084	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. 2013 , 368, 1781-90	388
1083	Myelofibrosis, JAK2 inhibitors and erythropoiesis. 2013 , 27, 1219-23	11
1082	SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. 2013 , 27, 1852-60	134

1081	JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count. 2013 , 7, 40-44	6
1080	The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications. 2013 , 37, 465-72	14
1079	A pickup in pseudokinase activity. 2013 , 41, 987-94	9
1078	A classification system based on a new wrapper feature selection algorithm for the diagnosis of primary and secondary polycythemia. 2013 , 43, 2118-26	8
1077	Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms. 2013 , 54, 922-33	6
1076	Update on the treatment of Ph-negative myeloproliferative neoplasms. 2013 , 2, 251-262	1
1075	Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment. 2013 , 2, 151-162	
1074	Treatment options for myelofibrosis and myeloproliferative neoplasia. 2013 , 2, 487-495	
1073	Focus on the epigenome in the myeloproliferative neoplasms. 2013 , 2013, 538-44	11
1072	Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained. 2013 , 54, 397-9	7
1071	The evolving treatment paradigm in myelofibrosis. 2013 , 54, 242-51	18
1070	Intrinsic resistance to JAK2 inhibition in myelofibrosis. 2013 , 19, 1729-39	13
1069	JAK2 mutation-related disease and thrombosis. 2013 , 39, 496-506	32
1068	Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. 2013 , 11, e1001576	58
1067	JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms: Clinical and Laboratory Findings. 2013 ,	0
1066	Adrenal incidentaloma and the Janus Kinase 2 V617F mutation: A case-based review of the literature. 2013 , 17, 153-6	1
1065	Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. 2013 , 12, 577-88	85
1064	SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol. 2013 , 453, 231-9	12

1063	New insights into the structure and function of the pseudokinase domain in JAK2. 2013 , 41, 1002-7	30
1062	Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia. 2013 , 30, 13-8	2
1061	What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?. 2013 , 20, 123-9	13
1060	Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. 2013 , 20, 169-75	12
1059	Hematopoietic stem cell transplantation for myelofibrosis: where are we now?. 2013 , 20, 130-6	4
1058	JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. 2013 , 2, e24574	16
1057	Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. 2013 , 288, 23814-22	16
1056	Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. 2013 , 191, 3578-93	12
1055	IGF-I in human growth: lessons from defects in the GH-IGF-I axis. 2013 , 71, 43-55	14
1054	Genome organization and the role of centromeres in evolution of the erythroleukaemia cell line HEL. 2013 , 2013, 225-40	6
1053	Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. 2013 , 73, 285-96	106
1052	Thrombocytosis. 2013 , 298-323	2
1051	SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. 2013 , 161, 811-20	12
1050	Molecular basis and clonal evolution of myeloproliferative neoplasms. 2013 , 51, 1889-96	7
1049	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. 2013 , 17, 1397-409	43
1048	JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. 2013 , 2013, 529-37	20
1047	Significance of cytogenetic abnormalities in patients with polycythemia vera. 2013 , 54, 2667-70	21
1046	Novel Approach to Diagnostics of Thrombocytosis: mRNA and miRNA Profiling of Blood Platelets. 2013 , 74, 413-417	0

1045	JAK-STAT signaling in stem cells. 2013 , 786, 247-67	38
1044	Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. 2013 , 17, 265-76	11
1043	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. 2013 , 54, 1989-95	53
1042	JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. 2013 , 2, e25025	23
1041	Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. 2013 , 4, 15-35	73
1040	Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. 2013 , 3, e109	45
1039	A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive onco kinases. 2013 , 3, e166	82
1038	The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. 2013 , 19, 327-35	35
1037	Inherited predisposition to myeloproliferative neoplasms. 2013 , 4, 237-53	40
1036	Diagnosis and treatment of myelofibrosis: a personal perspective. 2013 , 10, 439-453	
1035	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. 2013 , 98, 1689-96	9
1034	Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. 2013 , 121, 1188-99	34
1033	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- β in a murine model of polycythemia vera. 2013 , 121, 3692-702	110
1032	JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. 2013 , 121, 658-65	66
1031	Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. 2013 , 122, 93-9	19
1030	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 2013 , 121, 4388-95	74
1029	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. 2013 , 122, 1923-34	90
1028	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN- β . 2013 , 122, 1464-77	95

1027	Genetic loss of SH2B3 in acute lymphoblastic leukemia. 2013 , 122, 2425-32	92
1026	JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. 2013 , 122, 3787-97	79
1025	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. 2013 , 98, 1414-20	37
1024	Novel therapies in the classicalBCR/ABL-negative myeloproliferative neoplasms. 2013 , 2, 137-150	
1023	Stem cell transplantation in primary myelofibrosis of childhood. 2013 , 35, e120-2	7
1022	Search for mutations in signaling pathways in head and neck squamous cell carcinoma. 2013 , 30, 334-40	10
1021	Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. 2013 , 98, 1517-24	35
1020	Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. 2013 , 13, 760-73	24
1019	Treatment and management of myelofibrosis in the era of JAK inhibitors. 2013 , 7, 189-98	7
1018	Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib. 2013 , 5, CMT.S9566	
1017	Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. 2013 , 8, e52844	22
1016	Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. 2013 , 8, e59675	50
1015	Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. 2013 , 8, e63697	40
1014	The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. 2013 , 48, 128-32	16
1013	Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients. 2013 , 12, 5617-22	3
1012	Three dimensional quantitative structure-activity relationship of 5H-Pyrido[4,3-b]indol-4-carboxamide JAK2 inhibitors. 2013 , 14, 12037-53	2
1011	JAK2 and myeloproliferative neoplasms. 818-825	
1010	B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia. 2014 , 112, 537-50	6

1009	The azaindole framework in the design of kinase inhibitors. 2014 , 19, 19935-79	99
1008	Coexistence of primary myelofibrosis and chronic lymphocytic leukemia. 2014 , 101	
1007	Improved diagnosis of the transition to JAK2 (V617F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. 2014 , 9, e86401	4
1006	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. 2014 , 7, 89-101	38
1005	Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. 2014 , 60, 89-97	14
1004	. 2014 ,	7
1003	Contribution of chaperones to STAT pathway signaling. 2014 , 3, e970459	18
1002	Application of Novel Genotyping Microarray Technologies in Cancer Research. 2014 , 47-73	
1001	Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocythosis. 2014 , 41, 6737-42	9
1000	Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. 2014 , 67, 176-8	5
999	JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. 2014 , 111, 2295-300	59
998	Givinostat for the treatment of polycythemia vera. 2014 , 2, 841-850	1
997	The role of pacritinib in the management of myelofibrosis. 2014 , 7, 325-32	4
996	Orphan drugs for myelofibrosis. 2014 , 2, 391-405	1
995	Translational hematology. 2014 , 164, 487-96	
994	Therapy for myeloproliferative neoplasms: when, which agent, and how?. 2014 , 2014, 277-86	17
993	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. 2014 , 4, e174	19
992	Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice. 2014 , 28, 1627-35	11

991	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. 2014 , 55, 1968-79	18
990	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. 2014 , 7, 203-15	69
989	Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. 2014 , 458, 395-405	27
988	[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms]. 2014 , 155, 2074-81	1
987	Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. 2014 , 138, 1203-9	12
986	A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms. 2014 , 2014, 458457	5
985	Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis. 2014 , 4, 34-6	3
984	Calreticulin mutations in myeloproliferative neoplasms. 2014 , 5, e0035	11
983	Primary thrombocytosis in children. 2014 , 99, 620-8	32
982	The evolving genomic landscape of myeloproliferative neoplasms. 2014 , 2014, 287-96	51
981	How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?. 2014 , 2014, 268-76	20
980	Selective JAK inhibitors. 2014 , 6, 1439-71	28
979	Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. 2014 , 13, 2827-35	14
978	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. 2014 , 99, 465-73	137
977	A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. 2014 , 457, 323-34	192
976	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. 2014 , 111, E5401-10	183
975	An insight into JAK-STAT signalling in dermatology. 2014 , 39, 513-8	24
974	Application of enzyme bioluminescence for medical diagnostics. 2014 , 144, 175-97	9

973	Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. 2014 , 164, 83-93	22
972	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 2014 , 120, 513-20	139
971	Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. 2014 , 89, 295-301	12
970	Jakpot! New small molecules in autoimmune and inflammatory diseases. 2014 , 23, 7-11	91
969	Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. 2014 , 15, 791-804	79
968	Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. 2014 , 32, 1878-89	49
967	Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. 2014 , 14 Suppl, S23-35	21
966	Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection. 2014 , 18, 579-85	5
965	CHAPTER 5:Designed Macrocyclic Kinase Inhibitors. 2014 , 141-205	6
964	Molecular Determinants of Head and Neck Cancer. 2014 ,	2
963	Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. 2014 , 132, 75-86	8
962	Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study. 2014 , 15, 147	4
961	Red cell adhesion in human diseases. 2014 , 21, 186-92	22
960	Genetics of myeloproliferative neoplasms. 2014 , 20, 61-5	38
959	Venous and Arterial Thrombosis. 2014 , 277-296	4
958	Jak/STAT Signaling in HNC. 2014 , 163-177	2
957	Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. 2014 , 123, 3943-50	31
956	Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia. 2014 , 81, 60-8	11

955	Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report. 2014 , 17, 63-8	
954	Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus. 2014 , 16, R165	21
953	RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 2014 , 7, ra122	51
952	NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. 2014 , 38, 619-24	3
951	Detection of Janus Kinase 2 gene single point mutation in real samples with electrochemical DNA biosensor. 2014 , 429, 134-9	14
950	Thiophene carboxamide inhibitors of JAK2 as potential treatments for myeloproliferative neoplasms. 2014 , 24, 1968-73	6
949	Mutation in the first Ig-like domain of Kit leads to JAK2 activation and myeloproliferation in mice. 2014 , 184, 122-32	2
948	Successful management of acute bleeding in essential thrombocythemia using automated cell separator. 2014 , 50, 56-8	1
947	Are we altering the natural history of primary myelofibrosis?. 2014 , 38, 1004-12	23
946	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. 2014 , 50, 112-22	19
945	Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. 2014 , 71, 365-78	30
944	JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis. 2014 , 30, 4-8	0
943	Prevalence of JAK2 V617F mutation in west algerian population with chronic myeloproliferative neoplasms: A multicenter study. 2014 , 6, 138-144	
942	JAK2V617F allele burden in patients with myeloproliferative neoplasms. 2014 , 93, 791-6	13
941	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. 2014 , 93, 797-802	7
940	JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. 2014 , 99, 625-34	26
939	The Coagulation Consult. 2014 ,	1
938	JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. 2014 , 89, 517-23	29

937	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. 2014 , 123, e123-33	264
936	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. 2014 , 123, 3714-9	145
935	JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. 2014 , 123, 3139-51	58
934	How common are myeloproliferative neoplasms? A systematic review and meta-analysis. 2014 , 89, 581-7	97
933	Jak-2 positive myeloproliferative neoplasms. 2014 , 15, 147-56	8
932	DNA sequencing of cancer: what have we learned?. 2014 , 65, 63-79	37
931	Rethinking the diagnostic criteria of polycythemia vera. 2014 , 28, 1191-5	38
930	The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. 2014 , 28, 938-41	15
929	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. 2014 , 123, 2220-8	412
928	Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFN α treatment. 2014 , 28, 460-3	10
927	Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. 2014 , 100, 498-501	27
926	Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. 2014 , 32, 269-78	29
925	Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. 2014 , 211, 2213-30	68
924	Myeloproliferative Neoplasms. 2014 , 422-494	
923	Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death. 2014 , 15, 155-64	54
922	Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). 2014 , 93, 1953-63	56
921	JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. 2014 , 111, 15190-5	28
920	c-Abl activates janus kinase 2 in normal hematopoietic cells. 2014 , 289, 21463-72	9

919	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. 2014 , 512, 78-81	292
918	Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. 2014 , 27, 129-40	31
917	The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains. 2014 , 1844, 1835-41	18
916	Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?. 2014 , 27, 141-53	32
915	The molecular regulation of Janus kinase (JAK) activation. 2014 , 462, 1-13	178
914	Bioluminescence: Fundamentals and Applications in Biotechnology - Volume 1. 2014 ,	2
913	BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. 2014 , 28, 88-97	57
912	A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. 2014 , 27, 83-93	11
911	Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. 2014 , 93, 1965-76	26
910	Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. 2014 , 12, 2120-30	30
909	Minimal residual disease testing in hematologic malignancies and solid cancer. 2014 , 14, 699-712	16
908	The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 2014 , 7, 48	32
907	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. 2014 , 57, 144-58	46
906	Pearls & Oy-sters: polycythemia vera presenting with ischemic strokes in multiple arterial territories. 2014 , 82, e168-70	6
905	Assessing disease burden in patients with classic MPNs. 2014 , 27, 107-19	6
904	Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. 2014 , 42, 841-51	13
903	Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. 2014 , 46, 114-22	52
902	Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. 2014 , 93, 1467-72	4

901	Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. 2014 , 7, 18	25
900	Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. 2014 , 7, 25	15
899	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. 2014 , 46, 629-34	92
898	Effect of chemical modification on the ability of pyrrolidinium fullerene to induce apoptosis of cells transformed by JAK2 V617F mutant. 2014 , 20, 258-63	11
897	Novel myelofibrosis treatment strategies: potential partners for combination therapies. 2014 , 28, 2139-47	15
896	Efficacy of ruxolitinib for myelofibrosis. 2014 , 15, 1465-73	7
895	The future of JAK inhibition in myelofibrosis and beyond. 2014 , 28, 189-96	24
894	Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. 2014 , 15, 1265-76	27
893	Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. 2014 , 382, 616-621	63
892	Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. 2014 , 28, 375-86	19
891	Day of the dead: pseudokinases and pseudophosphatases in physiology and disease. 2014 , 24, 489-505	119
890	Towards precision medicine in childhood leukemia--insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia. 2014 , 352, 15-20	11
889	JAK/STAT pathway dysregulation in tumors: a Drosophila perspective. 2014 , 28, 96-103	59
888	JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. 2014 , 14, 525-33	9
887	Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. 2014 , 99, 1184-90	66
886	Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. 2014 , 20, 2051-9	109
885	Myeloproliferative disorders. 2014 , 32, 597-612	6
884	Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect?. 2014 , 133 Suppl 2, S107-11	11

883	Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. 2014 , 21, 579-84	106
882	Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells. 2014 , 42, 783-92.e1	7
881	Changing histopathological diagnostics by genome-based tumor classification. 2014 , 5, 444-59	12
880	Mutational spectrum defines primary and secondary myelofibrosis. 2014 , 99, 2-3	7
879	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. 2014 , 99, 292-8	35
878	The molecular basis of myeloid malignancies. 2014 , 90, 389-404	13
877	Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. 2014 , 124, 3924-31	32
876	A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. 2014 , 123, 1059-68	54
875	Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation. 2014 , 123, 520-9	18
874	Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. 2014 , 124, 1136-45	36
873	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. 2014 , 124, e21-32	89
872	Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. 2014 , 123, 2075-83	91
871	Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. 2014 , 124, 2280-4	42
870	JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. 2014 , 124, 2996-3006	30
869	Therapy for myeloproliferative neoplasms: when, which agent, and how?. 2014 , 124, 3529-37	71
868	The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. 2014 , 124, 3956-63	57
867	Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. 2014 , 99, e182-4	19
866	A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue. 2014 , 56, 327-9	1

865	Ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with myelofibrosis. 2014 , 3, 335-342	1
864	RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. 2015 , 13, 2345-2352	18
863	Molecular diagnostics of myeloproliferative neoplasms. 2015 , 95, 270-9	56
862	JAK/STAT Signalling and Haematological Malignancies. 2015 , 1-20	
861	Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with allelic burden. 2015 , 5, 28	12
860	Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. 2015 , 5, 643-651	
859	Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. 2015 , 5, 14	1
858	Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. 2015 , 126, 2479-83	29
857	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. 2015 , 125, 2649-55	89
856	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. 2015 , 125, 304-15	57
855	Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. 2015 , 125, 327-35	66
854	Ropeginterferon alfa-2b, a novel IFN α 2b, induces high response rates with low toxicity in patients with polycythemia vera. 2015 , 126, 1762-9	106
853	Polycythemia Vera Diagnosed after Esophageal Variceal Rupture. 2015 , 54, 2395-9	1
852	Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma. 2015 , 47, 867-74	13
851	Reassessment of H&E stained clot specimens and immunohistochemistry of phosphorylated Stat5 for histological diagnosis of MDS/MPN. 2015 , 47, 673-7	1
850	Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. 2015 , 5, 14538	24
849	Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. 2015 , 100, 893-7	38
848	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. 2015 , 13, 294	32

847	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. 2015 , 100, 479-88	174
846	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. 2015 , 90, n/a-n/a	
845	Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. 2015 , 35, 2042-9	29
844	Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. 2015 , 90, 864-70	24
843	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. 2015 , 90, 1116-21	10
842	Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. 2015 , 2015, 284706	70
841	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. 2015 , 9, 2687-94	3
840	Myeloproliferative neoplasms: Current molecular biology and genetics. 2016 , 98, 375-89	32
839	miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. 2016 , 6, e406	16
838	Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. 2016 , 21, 475-80	3
837	Novel CALR somatic mutations in essential thrombocythaemia. 2016 , 173, 797-801	4
836	A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era. 2016 , 11, 2134-2136	1
835	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. 2016 , 6, 368-81	159
834	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. 2016 , 77, 1125-42	26
833	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. 2016 , 11, 356-67	10
832	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. 2016 , 22, 432-40	95
831	JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. 2016 , 44, 24-9.e1	2
830	Thrombopoietin receptor is required for the oncogenic function of CALR mutants. 2016 , 30, 1759-63	48

829	Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. 2016 , 95, 739-44	28
828	Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation. 2016 , 12, 575-87	8
827	Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. 2016 , 22, 91-6	24
826	STAT5 in Cancer and Immunity. 2016 , 36, 226-37	86
825	Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). 2016 , 159, 17-25	4
824	Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. 2016 , 57, 1429-35	14
823	Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms. 2016 , 69, 155-63	17
822	Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. 2016 , 30, 94-103	22
821	JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation. 2016 , 35, 2235-46	20
820	Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. 2017 , 89, 209-218	29
819	Purification of SOCS (Suppressor of Cytokine Signaling) SH2 Domains for Structural and Functional Studies. 2017 , 1555, 173-182	3
818	JAK2-V617F activates β -integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. 2017 , 31, 1223-1226	11
817	Pseudokinases: update on their functions and evaluation as new drug targets. 2017 , 9, 245-265	49
816	Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. 2017 , 31, 2122-2131	21
815	Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. 2017 , 36, 3300-3311	17
814	Transforming growth factor β and interleukin 13-producing mast cells are associated with fibrosis in bone marrow. 2017 , 62, 180-186	12
813	SH2 Domains. 2017 ,	
812	Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. 2017 , 31, 1023-1038	38

811	Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. 2017 , 54, 73-77	21
810	The spleen microenvironment influences disease transformation in a mouse model of KIT-dependent myeloproliferative neoplasm. 2017 , 7, 41427	3
809	The role of the extracellular matrix in primary myelofibrosis. 2017 , 7, e525	30
808	Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. 2017 , 98, 577-583	17
807	Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. 2017 , 58, 1-11	16
806	A myeloid tumor suppressor role for. 2017 , 214, 753-771	4
805	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. 2017 , 35, 533-550	87
804	Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors. 2017 , 7, 10353-10360	20
803	Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. 2017 , 34, 83	21
802	Molecular Biology, Genomics, Proteomics, and Mouse Models of Human Cancer. 2017 , 1-31	
801	HiJAKing the epigenome in leukemia and lymphoma. 2017 , 58, 2540-2547	2
800	Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. 2017 , 10, 393-404	16
799	Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. 2017 , 22, 599-606	5
798	Budd-Chiari syndrome and veno-occlusive disease. 2017 , 1248-1271.e6	
797	JAK2 inhibitors for myeloproliferative neoplasms: what is next?. 2017 , 130, 115-125	63
796	Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms. 2017 , 425, 43-52	8
795	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. 2017 , 58, 2786-2798	12
794	Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. 2017 , 178, 689-698	25

793	A life-threatening ruxolitinib discontinuation syndrome. 2017 , 92, 833-838	26
792	Investigational Janus kinase inhibitors in development for myelofibrosis. 2017 , 26, 723-734	9
791	Molecular Genetics of Endometrial Carcinoma. 2017 ,	1
790	Endometrial Carcinoma: Specific Targeted Pathways. 2017 , 943, 149-207	37
789	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. 2017 , 31, 139-150	6
788	The thrombopoietin/MPL axis is activated in the Gata1 mouse model of myelofibrosis and is associated with a defective RPS14 signature. 2017 , 7, e572	19
787	A Genetic Screen Reveals an Unexpected Role for Yorkie Signaling in JAK/STAT-Dependent Hematopoietic Malignancies in. 2017 , 7, 2427-2438	12
786	The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. 2017 , 31, 613-626	16
785	Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. 2017 , 31, 627-642	21
784	Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. 2017 , 8, 618-621	22
783	JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules. 2017 , 8, 614-617	19
782	Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm. 2017 , 96, 1399-1401	5
781	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. 2017 , 60, 11-17	25
780	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. 2017 , 10, 617-625	21
779	Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality. 2017 , 31, 565-576	3
778	Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. 2017 , 31, 2717-2725	9
777	Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. 2017 , 31, 1845-1854	17
776	Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. 2017 , 92, 909-914	9

775	JAK1 somatic mutation in a myeloproliferative neoplasm. 2017 , 102, e324-e327	8
774	Diagnosis and classification of hematologic malignancies on the basis of genetics. 2017 , 130, 410-423	113
773	The Impact of Mean Platelet Volume (MPV) and JAK-2 Mutation on Thrombosis in Chronic Myeloproliferative Diseases. 2017 , 33, 181-187	7
772	pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. 2017 , 37, 2295-2307	2
771	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. 2017 , 23, 1095-1101	65
770	Unusual Myelodysplastic and Myelodysplastic/Myeloproliferative Neoplasms. 2017 , 752-759	
769	Myeloproliferative Neoplasms. 2017 , 816-829	
768	Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. 2017 , 56, 354-362	10
767	Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. 2017 , 292, 1826-1846	7
766	Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. 2017 , 31, 1962-1974	47
765	Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). 2017 , 127, 72-86	14
764	Introduction to a review series on myeloproliferative neoplasms. 2017 , 129, 659	1
763	Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. 2017 , 129, 680-692	131
762	Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. 2017 , 31, 41-57	7
761	Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma. 2017 , 15, 348-357	10
760	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. 2017 , 129, 667-679	275
759	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. 2017 , 102, 7-17	44
758	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. 2017 , 102, 18-29	8

757	Kinase signaling and targeted therapy for primary myelofibrosis. 2017 , 48, 32-38	5
756	Investigation of T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) polymorphisms in essential thrombocythaemia (ET). 2017 , 22, 361-367	2
755	Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. 2017 , 22, 354-360	1
754	Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. 2017 , 7, 370-376	7
753	Myeloproliferative Disorders. 2017 , 31, 1029-1044	7
752	Exome-wide association study of plasma lipids in >300,000 individuals. 2017 , 49, 1758-1766	310
751	Clinical and laboratory assessment of a patient with thrombocytosis. 2017 , 78, 558-564	4
750	Thrombocytosis in 715 Dogs (2011-2015). 2017 , 31, 1691-1699	15
749	Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. 2017 , 12, 424-431	5
748	Familial MPN Predisposition. 2017 , 12, 442-447	9
747	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. 2017 , 130, 1768-1771	45
746	Mutations in myeloproliferative neoplasms - their significance and clinical use. 2017 , 10, 961-973	17
745	Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?. 2017 , 44, 97-104	11
744	DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms. 2017 , 13, 4641-4650	5
743	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. 2017 , 187, 1879-1892	12
742	Epigenetics in Myeloproliferative Neoplasms. 2017 , 21, 1660-1667	20
741	Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. 2017 , 108, 1907-1912	12
740	Clinical significance of circulating microparticles in Ph myeloproliferative neoplasms. 2017 , 14, 2531-2536	24

739	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. 2017 , 130, 1889-1897	101
738	Immunotherapy based approaches in myelofibrosis. 2017 , 10, 903-914	7
737	Myeloproliferative neoplasms: from origins to outcomes. 2017 , 130, 2475-2483	58
736	Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. 2017 , 26, 112-125	26
735	The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. 2017 , 18, 1929-1938	12
734	Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. 2017 , 3,	25
733	Cancer stem cells and differentiation therapy. 2017 , 39, 1010428317729933	49
732	JAK2 variations and functions in lung adenocarcinoma. 2017 , 39, 1010428317711140	13
731	Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). 2017 , 77, 14.40.1-14.40.19	13
730	Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. 2017 , 60, 31-35	25
729	Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction. 2017 , 7, 4613	5
728	Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review. 2017 , 8, 375-378	6
727	New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias. 2017 , 60, 6119-6136	10
726	Kinase Inhibitor Screening in Myeloid Malignancies. 2017 , 31, 693-704	3
725	Hmga2 promotes the development of myelofibrosis in Jak2 knockin mice by enhancing TGF- β and Cxcl12 pathways. 2017 , 130, 920-932	12
724	Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. 2017 , 11, 6	9
723	A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. 2017 , 31, 934-944	36
722	Chromosomes and Chromosomal Instability in Human Cancer. 2017 , 241-262	

721	Molecular Biology of Leukemias. 2017 , 505-559	
720	Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. 2017 , 19, 92-98	23
719	After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. 2017 , 31, 101-118	13
718	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. 2017 , 105, 59-69	9
717	Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. 2017 , 31, 1136-1144	53
716	Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. 2017 , 98, 85-93	27
715	Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. 2017 , 31, 821-828	22
714	Malignancy and Janus Kinase Inhibition. 2017 , 43, 79-93	17
713	BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options. 2017 , 31, 11-16	50
712	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. 2017 , 8, 54082-54095	22
711	Myeloproliferative neoplasms: from origins to outcomes. 2017 , 2017, 470-479	10
710	V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. 2017 , 1, 968-971	21
709	Myeloid Cell Origins, Differentiation, and Clinical Implications. 2017 , 857-875	1
708	Molecular Testing in Myeloproliferative Neoplasms. 2017 , 435-447	
707	Novel Intra-cellular Targeting Agents in Rheumatic Disease. 2017 , 1044-1060	1
706	Cancer as a Paradigm for Translational and Clinical Biomedical Research. 2017 , 587-607	
705	The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. 2017 , 8, 59	33
704	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. 2017 , 8, 234	23

703	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. 2017 , 2017, 9876819	5
702	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. 2017 , 56, 1705-1710	2
701	Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis. 2017 , 12, e0166014	3
700	A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. 2017 , 12, e0177123	24
699	Targeting the Bone Marrow Niche in Hematological Malignancies. 2017 , 155-175	1
698	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. 2017 , 9, 89	23
697	Predicting pathogenic genes for primary myelofibrosis based on a system-network approach. 2018 , 17, 186-192	0
696	INTERLEUKIN 1 β LEVEL AND C- REACTIVE PROTEIN ROLES IN PRIMARY MYELOFIBROSIS PATIENTS TREATED WITH HYDROXYUREA AND RUXOLITINIB. 2017 , 8, 30-34	
695	Jak2a regulates erythroid and myeloid hematopoiesis during zebrafish embryogenesis. 2017 , 14, 758-763	3
694	Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia. 2017 , 8, 32476-32491	3
693	HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?. 2017 , 8, 28187-28202	7
692	Emerging drugs for the treatment of Myelofibrosis. 2018 , 23, 37-49	9
691	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. 2018 , 107, 681-688	10
690	Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. 2018 , 55, 215-222	7
689	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. 2018 , 37, 3981-3997	17
688	Impact of hydroxycarbamide and interferon- β on red cell adhesion and membrane protein expression in polycythemia vera. 2018 , 103, 972-981	7
687	Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017. 2018 , 34, 227-232	1
686	Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents. 2018 , 107-134	

685	Targeting TGF- β signaling for the treatment of fibrosis. 2018 , 68-69, 8-27	116
684	Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. 2018 , 67, 67-74	7
683	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study. 2018 , 168, 317-325	101
682	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. 2018 , 8, 15	221
681	Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. 2018 , 131, 649-661	50
680	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. 2018 , 32, 1035-1038	35
679	Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. 2018 , 131, 782-786	57
678	Driver mutations in primary myelofibrosis and their implications. 2018 , 25, 129-135	8
677	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. 2018 , 22, 98-103	4
676	Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. 2018 , 65, 42-48	11
675	Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. 2018 , 11, 247-252	1
674	Interleukin-6: designing specific therapeutics for a complex cytokine. 2018 , 17, 395-412	272
673	Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio [®] BD Digital PCR System. 2018 , 1768, 257-273	0
672	Myeloid cells regulate plasma LDL-cholesterol levels. 2018 , 29, 233-239	2
671	Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?. 2018 , 128, 88-100	22
670	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. 2018 , 103, 40-50	22
669	Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G>T (p.Met535Ile). 2018 , 71, 180-184	1
668	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. 2018 , 107, 92-97	4

667	CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. 2018 , 23, 208-211		7
666	Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. 2018 , 107, 173-184		8
665	MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients. 2018 , 59, 844-854		4
664	Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. 2018 , 143, 449-463		31
663	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell</i> , 2018 , 33, 29-43.e7	24-3	113
662	Defective WNT signaling associates with bone marrow fibrosis-a cross-sectional cohort study in a family with WNT1 osteoporosis. 2018 , 29, 479-487		6
661	Recent advances in the diagnosis and management of primary myelofibrosis. 2018 , 33, 679-690		8
660	Detection of the Janus kinase 2 V617F mutation using a locked nucleic-acid, real-time polymerase chain reaction assay. 2018 , 7, 658		
659	Molecular Hematopathology. 2018 , 712-760.e18		0
658	Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article. 2018 , 97, e11331		2
657	Myeloproliferative and Overlap Myelodysplastic/Myeloproliferative Neoplasms. 2018 , 488-538.e4		3
656	Concomitant presence of JAK2V617F mutation and BCR-ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report). 2018 , 18, 1001-1006		1
655	Ruxolitinib for the Treatment of Essential Thrombocythemia. 2018 , 2, e56		5
654	MPL-mutated essential thrombocythemia: a morphologic reappraisal. 2018 , 8, 121		13
653	Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 Mice. 2018 , 123, e35-e47		93
652	Alterations in Blood Components. 2018 , 249-293		4
651	Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells. 2018 , 13, e0197233		2
650	Fungal metabolite (+)-terrein suppresses IL-6/sIL-6R-induced CSF1 secretion by inhibiting JAK1 phosphorylation in human gingival fibroblasts. 2018 , 4, e00979		7

649	The molecular details of cytokine signaling via the JAK/STAT pathway. 2018 , 27, 1984-2009	194
648	The Cellular and Molecular Mechanisms of Hematopoiesis. 2018 , 1-23	0
647	Expression of CD markers in JAK2 positive myeloproliferative neoplasms: Prognostic significance. 2018 , 12, 373	4
646	Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. 2018 , 132, 2707-2721	37
645	Genetic Aspects of Hematopoietic Malignancies. 2018 , 201-234	0
644	Cooccurring V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. 2018 , 132, 2695-2699	1
643	Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera. 2018 , 57, 3293-3297	0
642	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. 2018 , 9, 2264	18
641	Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. 2018 , 9, 251-259	2
640	Emerging therapies for the treatment of essential thrombocythemia. 2018 , 6, 567-575	
639	JAK2-V617F promotes venous thrombosis through $\alpha\text{IIb}\beta\text{3}$ integrin activation. 2018 , 128, 4359-4371	56
638	Neural Crossroads in the Hematopoietic Stem Cell Niche. 2018 , 28, 987-998	18
637	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. 2018 , 93, 824-840	73
636	Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells. 2018 , 117, 271-279	3
635	From Drosophila Blood Cells to Human Leukemia. 2018 , 1076, 195-214	7
634	Drosophila Models for Human Diseases. 2018 ,	6
633	Biology of Erythropoiesis, Erythroid Differentiation, and Maturation. 2018 , 297-320.e14	1
632	NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin. 2018 , 9, 527	1

631	Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. 2018,	
630	Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. 2018, 10, 9-17	8
629	Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children. 2018, 994-1004.e7	
628	Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase. 2017, 8, 361	42
627	Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment. 2018, 8, 119	9
626	The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. 2018, 10,	37
625	A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera. 2018, 10,	1
624	Proposed Molecular and miRNA Classification of Gastric Cancer. 2018, 19,	40
623	Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal. 2018, 132, 791-803	15
622	Serum chitotriosidase: a circulating biomarker in polycythemia vera. 2018, 23, 793-802	2
621	Austrian recommendations for the management of polycythemia vera. 2018, 130, 535-542	3
620	Polycythemia vera: diagnosis, clinical course, and current management. 2018, 48, 698-710	5
619	JAK2 and Endothelial Function: New Options for Anti-Thrombotic Therapies. 2018, 118, 1512-1514	
618	"Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway. 2018, 8, 287	155
617	Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches. 2018, 23,	5
616	Cytopenias: Reactive and Neoplastic. 2018, 17-79	1
615	Molecular Basis of Lymphoid and Myeloid Diseases. 2018, 299-328	1
614	STAT3: a multifaceted oncoprotein. 2018, 36, 1-14	80

613	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. 2018 , 32, 849-864	17
612	The regulation of JAKs in cytokine signaling and its breakdown in disease. 2019 , 118, 48-63	83
611	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. 2019 , 185, 136-139	7
610	Cancer immune therapy for myeloid malignancies: present and future. 2019 , 41, 97-109	11
609	Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. 2019 , 8,	62
608	JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. 2019 , 145, 3376-3388	34
607	THROMBOCYTOSIS: A RETROSPECTIVE STUDY OF 573 DOGS (2016-2017). 2019 , 20,	0
606	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. 2019 , 14, e0220189	2
605	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. 2019 , 14, 460-468	12
604	Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing. 2019 , 14, 376-385	1
603	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. <i>Cancer Cell</i> , 2019 , 36, 123-138.e10	24.3 43
602	Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms. 2019 , 173-183	
601	Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method. 2019 , 10, 235-241	5
600	Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant. 2019 , 123, 154753	2
599	Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia. 2019 , 219, 440-444	
598	Experimental Modeling of Myeloproliferative Neoplasms. 2019 , 10,	6
597	A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression. 2019 , 14, e0221635	2
596	Balancing STAT Activity as a Therapeutic Strategy. 2019 , 11,	9

595 Myeloproliferative neoplasms. **2019**, 87-100

594 JAK, an Oncokinase in Hematological Cancer. **2019**,

593 Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. **2019**, 26, 903-e64 10

592 Momelotinib for the treatment of myelofibrosis. **2019**, 20, 1943-1951 7

591 Thermal cues drive plasticity of desiccation resistance in montane salamanders with implications for climate change. **2019**, 10, 4091 17

590 JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. **2019**, 134, 1832-1846 25

589 Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. **2019**, 14, e0222944 21

588 Mutant calreticulin in myeloproliferative neoplasms. **2019**, 134, 2242-2248 26

587 Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. **2019**, 9, 14159 22

586 Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. **2019**, 19, 590 8

585 Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation. **2019**, 25, 5901-5912 25

584 Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. **2019**, 19, 121 26

583 Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis. **2019**, 58, 747-755 5

582 Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation. **2019**, 82, 11-14

581 The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. **2019**, 12, 437-448 14

580 V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease. **2019**, 120, 15746-15755 8

579 A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. **2019**, 142, 105-112 2

578 From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era. **2019**, 155-172

577	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. 2019,	
576	Emerging drugs for essential thrombocythemia. 2019, 24, 93-105	1
575	Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient. 2019, 41 Suppl 1, 142-150	2
574	Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity. 2019, 12,	5
573	Guideline on myeloproliferative neoplasms: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2019. 2019, 41 Suppl 1, 1-73	1
572	Identification and transcriptome analysis of erythroblastic island macrophages. 2019, 134, 480-491	56
571	Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation. 2019, 8, 10	10
570	Gastric Cancer In The Precision Medicine Era. 2019,	
569	SOHO State of the Art Updates and Next Questions: Myelofibrosis. 2019, 19, 191-199	0
568	The Role of New Technologies in Myeloproliferative Neoplasms. 2019, 9, 321	21
567	Genomics and Precision Medicine: Molecular Diagnostics Innovations Shaping the Future of Healthcare in Qatar. 2019, 2019, 1-11	8
566	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. 2019, 62, 3898-3923	38
565	Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. 2019, 49, 840-863	18
564	Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. 2019, 11,	16
563	Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling. 2019, 144, 224-235	13
562	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. 2019, 94, 599-610	50
561	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. 2019, 104, 659-668	40
560	Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study. 2019, 51, 1179-1184	20

559	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. 2019 , 9, 42	12
558	Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha. 2019 , 12, 36	13
557	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. 2019 , 9, 778-795	26
556	Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia. 2019 , 44, 492-498	
555	Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. 2019 , 72, 60-71.e11	4
554	Hipk is required for JAK/STAT activity during development and tumorigenesis. 2019 , 14, e0226856	4
553	Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies. 2019 ,	2
552	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. 2019 , 9, 1186	83
551	Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. 2019 , 59, 5002-5012	16
550	Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1. 2019 , 11,	4
549	The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation. 2019 , 11,	6
548	AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells. 2019 , 3, e233	4
547	Vascular endothelial cell expression of JAK2 is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. 2019 , 104, 70-81	49
546	Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. 2019 , 41, 5-19	39
545	Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. 2019 , 143, 1549-1559.e6	10
544	Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar. 2019 , 689, 34-42	14
543	Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. 2019 , 25, 2323-2335	17
542	Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. 2019 , 104, 937-946	3

541	Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango". 2019 , 70, 24-30	4
540	Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. 2019 , 51, 301-307	4
539	The sympathomimetic agonist mirabegron did not lower -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. 2019 , 104, 710-716	22
538	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. 2019 , 85, 290-298	12
537	Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis. 2019 , 25, 2956-2962	12
536	Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study. 2019 , 23, 845-874	3
535	CDK6 coordinates mutant MPN via NF- κ B and apoptotic networks. 2019 , 133, 1677-1690	23
534	International external quality assurance of JAK2 V617F quantification. 2019 , 98, 1111-1118	2
533	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. 2019 , 60, 1036-1042	1
532	Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. 2019 , 94, 62-73	6
531	Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls. 2019 , 98, 111-118	5
530	The Role of Caspase Genes Polymorphisms in Genetic Susceptibility to Philadelphia-Negative Myeloproliferative Neoplasms in a Portuguese Population. 2019 , 25, 961-969	6
529	Erythropoiesis, EPO, macrophages, and bone. 2019 , 119, 36-41	20
528	Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. 2020 , 38, 610-620	3
527	Mutational profiling in myelofibrosis: implications for management. 2020 , 111, 192-199	7
526	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. 2020 , 34, 799-810	22
525	Myeloproliferative neoplasms. 2020 , 555-588	
524	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. 2020 , 34, 510-521	23

523	Cardiovascular Disease, Aging, and Clonal Hematopoiesis. 2020 , 15, 419-438	39
522	JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. 2020 , 40, 100634	18
521	Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. 2020 , 34, 1075-1089	15
520	Myeloproliferative Neoplasms. 2020 , 1821-1835.e4	
519	The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. 2020 , 111, 206-216	6
518	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. 2020 , 33, 1092-1103	9
517	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. 2020 , 95, 97-115	54
516	Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. 2020 , 111, 182-191	9
515	The role of calreticulin mutations in myeloproliferative neoplasms. 2020 , 111, 200-205	11
514	Calreticulin Mutation by Immunohistochemistry: Can It Replace PCR?. 2020 , 28, 621-626	1
513	Novel targets to cure primary myelofibrosis from studies on Gata1 mice. 2020 , 72, 131-141	4
512	Autoinhibition can identify rare driver mutations and advise pharmacology. 2020 , 34, 16-29	15
511	JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F-MPNs. 2020 , 4, 4554-4559	2
510	Risk factors for vascular liver diseases: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFL), and ERN-rare liver. 2020 , 44, 410-419	3
509	Bone Marrow Microenvironment in Health and Disease. 2020 , 1-11	0
508	The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. 2020 , 21,	2
507	-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. 2020 , 63, 14921-14936	4
506	Zebrafish for thrombocytopoiesis- and hemostasis-related researches and disorders.. 2020 , 2, 44-49	1

505	Novel therapeutics in myeloproliferative neoplasms. 2020 , 13, 162	15
504	Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data. 2020 , 13, 12367-12382	8
503	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. 2020 , 42, 671-684	2
502	The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. 2020 , 15, 409-418	6
501	Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN. 2020 , 12,	1
500	Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. 2020 , 12,	3
499	Clonal hematopoiesis: mechanisms driving dominance of stem cell clones. 2020 , 136, 1590-1598	23
498	MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. 2020 , 136, 2591-2595	3
497	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. 2020 , 4, e424	18
496	Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. 2020 , 12,	8
495	A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays. 2020 , 61, 3052-3065	1
494	Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. 2020 , 12,	6
493	Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. 2020 , 10, 579221	3
492	Clonal Hematopoiesis, Cardiovascular Diseases and Hematopoietic Stem Cells. 2020 , 21,	5
491	Rapidly progressive cognitive impairment: an unusual presentation of cerebral venous thrombosis caused by JAK2 V617F-positive primary myelofibrosis: A case report. 2020 , 99, e21757	0
490	Murine Models of Myelofibrosis. 2020 , 12,	8
489	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. 2020 , 9,	7
488	E-Cigarette Exposure Decreases Bone Marrow Hematopoietic Progenitor Cells. 2020 , 12,	3

487	MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. 2020 , 9,	9
486	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. 2020 , 12,	2
485	Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. 2020 , 257, 507-516	2
484	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. 2020 , 4, 3677-3687	17
483	Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date. 2020 , 16, 889-901	4
482	The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms. 2020 , 9, 9445-9453	5
481	Computational Study of Pyrimidin-2-Aminopyrazol-Hydroxamate-based JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. 2020 , 41, 542-551	2
480	Metadynamics as a Postprocessing Method for Virtual Screening with Application to the Pseudokinase Domain of JAK2. 2020 , 60, 4403-4415	2
479	Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocythemic Patients. 2020 , 12, e2020022	
478	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. 2020 , 42, 100712	7
477	Survival following allogeneic transplant in patients with myelofibrosis. 2020 , 4, 1965-1973	23
476	Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. 2020 , 42, 100708	3
475	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. 2020 , 4, 2477-2488	6
474	HMGA Proteins in Hematological Malignancies. 2020 , 12,	5
473	Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults. 2020 , 15, 141-148	3
472	Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2 Method. 2020 , 10,	5
471	Ruxolitinib for the treatment of graft-versus-host disease. 2020 , 16, 347-359	5
470	Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. 2020 , 30, 3280-3295.e6	5

469	JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses. 2020 , 42, 331-334	
468	Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. 2020 , 23, 721-727	21
467	Myelofibrosis biology and contemporary management. 2020 , 191, 152-170	21
466	A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients. 2020 , 20, 205	0
465	Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration. 2020 , 10,	11
464	Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. 2020 , 191, 21-36	3
463	Discovery of a novel kinase hinge binder fragment by dynamic undocking. 2020 , 11, 552-558	6
462	A novel translocation t(10;17)(p13;q11.2) harboring two cryptic deletions identified by array-CGH and characterized by SUZ12 overexpression in a patient with chronic thrombocytosis. 2020 , 59, 661-666	
461	Immunotherapy in Myeloproliferative Diseases. 2020 , 9,	7
460	Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms. 2020 ,	0
459	Clonal hematopoiesis in hematological disorders: Three different scenarios. 2020 , 83, 57-65	5
458	Targeting cancer stem cell pathways for cancer therapy. 2020 , 5, 8	389
457	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. 2020 , 26, 181-187	69
456	Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. 2020 , 297, 120-126	9
455	Mutant Calreticulin in the Myeloproliferative Neoplasms. 2020 , 4, e333	8
454	Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe Mice. 2020 , 34, 145-152	19
453	Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. 2020 , 287, 448-454	13
452	The SMAC mimetic LCL-161 selectively targets JAK2 mutant cells. 2020 , 9, 1	21

451	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. 2020 , 26, 893-901	7
450	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. 2020 , 69, 315-324	7
449	Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. 2020 , 367, 643-652	47
448	Maintenance Strategies After Hematopoietic Cell Transplantation. 2020 , 40, 727-740	0
447	Fedratinib in myelofibrosis. 2020 , 4, 1792-1800	27
446	CDK6 Inhibition: A Novel Approach in AML Management. 2020 , 21,	11
445	STAT3-driven hematopoiesis and lymphopoiesis abnormalities are dependent on serine phosphorylation. 2020 , 130, 155059	3
444	Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease. 2020 , 35, 219-225	7
443	Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. 2020 , 72, 486-526	62
442	Bone marrow niche dysregulation in myeloproliferative neoplasms. 2020 , 105, 1189-1200	9
441	Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core. 2020 , 63, 5324-5340	11
440	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. 2020 , 20, 415-421	16
439	Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. 2020 , 73, 728-736	3
438	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. 2020 , 135, 191-207	23
437	Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. 2020 , 4, 218-228	34
436	N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm. 2020 , 4, 312-321	24
435	Guidance on changing therapy choice in myelofibrosis. 2020 , 4, 607-610	1
434	Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes. 2020 , 12,	8

433	Mouse Models of Myeloid Malignancies. 2021 , 11,	1
432	Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. 2021 , 14, 293-296	1
431	Stathmin 1 deficiency induces erythro-megakaryocytic defects leading to macrocytic anemia and thrombocythemia in Stathmin 1 knock out mice. 2021 , 87, 102522	1
430	Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals. 2021 , 10, 365-371	
429	Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. 2021 , 137, 1920-1931	4
428	The Microenvironment in Myeloproliferative Neoplasms. 2021 , 35, 205-216	6
427	Prevalence of definite antiphospholipid syndrome in carriers of the JAK2 mutation. 2021 , 198, 55-61	1
426	Differential expression of circular RNAs in bone marrow-derived exosomes from essential thrombocythemia patients. 2021 , 45, 869-881	2
425	Germline genetic factors influence the outcome of interferon- α therapy in polycythemia vera. 2021 , 137, 387-391	5
424	Lab tests for MPN.. 2022 , 366, 187-220	
423	Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms. 2021 , 19, 205873922110065	
422	Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms. 2021 , 21, 204	1
421	Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology. 2021 ,	2
420	Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These "". 2021 , 10,	2
419	Applications of next-generation sequencing in hematologic malignancies. 2021 , 82, 859-870	0
418	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With -Mutant Chronic Myeloproliferative Neoplasms. 2021 , 11, 637420	8
417	Polycythaemia vera: molecular genetics, diagnostics and therapeutics. 2021 , 116, 617-627	2
416	A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms. 2021 , 13,	3

415	Janus Kinases in Leukemia. 2021 , 13,	6
414	The NCI Genomic Data Commons. 2021 , 53, 257-262	11
413	Frequency of Zygoty in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective. 2021 , 22, 559-564	1
412	JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms. 2021 , 106, 1783-1784	1
411	Mucosal Epithelial Jak Kinases in Health and Diseases. 2021 , 2021, 6618924	0
410	HOXA9 acts as a regulatory switch in acute myeloid leukaemia and myeloproliferative neoplasms.	
409	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. 2021 , 28, 514-523.e9	42
408	Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. 2021 , 165, 26-33	
407	ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis. 2021 , 22,	0
406	The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms. 2021 , 22,	0
405	Recent advances in prognostication and treatment of polycythemia vera. 2021 , 10, 29	0
404	Jejunal variceal rupture in a patient with myelofibrosis: a case report. 2021 , 14, 542-545	
403	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. 2021 , 11, 53	5
402	A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34 bone marrow cells from patients with JAK2V617F-positive polycythemia vera. 2021 , 21, 351	0
401	Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. 2021 , 10,	2
400	Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms. 2021 , 16, e0247858	0
399	Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. 2021 , 28, 502-513.e6	5
398	The role of new technologies in myeloproliferative neoplasms: Application of next-generation sequencing in myelofibrosis. 2021 , 43, 1070-1077	

397	Precision medicine in myeloid malignancies. 2021 ,	5
396	Current Clinical Investigations in Myelofibrosis. 2021 , 35, 353-373	2
395	The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies. 2021 , 5, 2040-2052	2
394	Low V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional or Gene Mutations. 2021 , 12,	0
393	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. 2021 , 12, 341	3
392	The Role of Megakaryocytes in Myelofibrosis. 2021 , 35, 191-203	3
391	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. 2021 , 35, 409-429	2
390	Disease modifying agents of myeloproliferative neoplasms: a review. 2021 , 56, S26-S33	3
389	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. 2021 , 135, 991-1007	1
388	Genetics of Myeloproliferative Neoplasms. 2021 , 35, 217-236	2
387	Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. 2021 , 22,	3
386	Polycythemia Vera Presenting as Hemorrhagic Stroke. 2021 , 12, 601-602	0
385	MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes. 2021 , 19, 233	1
384	Screening of somatic mutations in the JAK2 and CALR genes by high-resolution melting curve analysis. 2021 , 66, 315-320	
383	Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations. 2021 , 97, 47-56.e5	1
382	Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis. 2021 , 479, 755-764	1
381	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?. 2021 , 13,	1
380	JAK-STAT in Early Hematopoiesis and Leukemia. 2021 , 9, 669363	7

379	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. 2021 , 156, 679-690	2
378	Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. 2021 , 4, 117-128	1
377	Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. 2021 , 41, 197-205	0
376	A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. 2021 ,	3
375	Molecular pathogenesis of the myeloproliferative neoplasms. 2021 , 14, 103	10
374	Polymerase chain reaction-restriction fragment length polymorphism method for detection of Calreticulin type-1 and type-2 mutations in myeloproliferative neoplasm. 2021 , 14, 213-220	
373	The Prevalence of Gene Mutations in Patients with --Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis. 2021 , 13,	3
372	Functional Consequences of Mutations in Myeloproliferative Neoplasms. 2021 , 5, e578	4
371	Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. 2021 , 13,	1
370	Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms. 2021 , 100, 2567-2574	1
369	Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. 2021 , 21, 483-488	
368	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. 2021 , 13,	3
367	CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of V617F Somatic Mutation in Myeloproliferative Neoplasms. 2021 , 11,	2
366	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. 2021 ,	1
365	High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells. 2021 , 11, 137	1
364	Indoloxotriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant. 2021 , 77,	1
363	Hematopoiesis during Ontogenesis, Adult Life, and Aging. 2021 , 22,	4
362	The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN. 2021 , 13,	2

361	Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. 2021 , 5, 3515-3527	2
360	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. 2021 , 10,	1
359	NK Cells in Myeloproliferative Neoplasms (MPN). 2021 , 13,	
358	Phase II study of single-agent nivolumab in patients with myelofibrosis. 2021 , 100, 2957-2960	3
357	The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. 2021 , 13,	0
356	Emerging Role of Acquired Mutations and Clonal Hematopoiesis in Atherosclerosis - Beyond Conventional Cardiovascular Risk Factors. 2021 ,	2
355	Current and future status of JAK inhibitors. 2021 , 398, 803-816	17
354	Circulating platelet count and glycans. 2021 , 28, 431-437	0
353	Improving the investigative approach to polycythaemia vera: a critical assessment of current evidence and vision for the future. 2021 , 8, e605-e612	1
352	The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. 2021 , 9,	0
351	Chemical Probes for Understudied Kinases: Challenges and Opportunities. 2021 ,	1
350	The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. 2021 , 22,	
349	Genomic Profiling of a Randomized Trial of Interferon- γ Versus Hydroxyurea in MPN Reveals Mutation-Specific Responses. 2021 ,	3
348	Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease. 2021 , 5, 5349-5359	2
347	Emerging role of BAD and DAD1 as potential targets and biomarkers in cancer. 2021 , 22, 811	0
346	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. 2021 , 35, 3339-3351	7
345	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. 2021 , 11, 751668	0
344	Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. 2021 , 193, 114760	5

343	Ph-Negative Myeloproliferative Neoplasms: Diagnosis and Treatment Challenges in Russia (the Case of Saint Petersburg). 2021 , 14, 45-52	1
342	Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives. 2021 , 12, 430-438	4
341	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. 2021 , 36, 45-62	7
340	Low-Risk Essential Thrombocythemia: A Comprehensive Review. 2021 , 5, e521	3
339	Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. 2020 , 9, 2039-2051	11
338	Murine Models of Hematopoietic Disease: Pathologic Analysis and Characterization. 2008 , 45-80	2
337	Characterization of Ligand Binding to Pseudokinases Using a Thermal Shift Assay. 2017 , 1636, 91-104	12
336	Altered Apoptosis in AML. 2007 , 133-161	1
335	Integrative oncogenomic analysis of microarray data in hematologic malignancies. 2010 , 576, 231-77	5
334	The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression. 2020 , 1219, 259-293	2
333	Mechanisms of Thrombogenesis. 2012 , 57-67	2
332	Erythropoiesis: an overview. 2009 , 3-18	2
331	Mechanism of erythropoietin receptor activation. 2009 , 175-196	2
330	Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. 2017 , 143, 807-820	7
329	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
328	The safety of JAK kinase inhibitors for the treatment of myelofibrosis. 2021 , 20, 139-154	4
327	Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. 2021 , 5, e516	7
326	Hipk is required for JAK/STAT activity and promotes hemocyte-derived tumorigenesis.	1

325	Single cell mutational profiling delineates clonal trajectories in myeloid malignancies.	6
324	Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms.	1
323	Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient. 2009 , 2009,	2
322	Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders. 2019 , 129, 1519-1521	2
321	The survival kinases Akt and Pim as potential pharmacological targets. 2005 , 115, 2618-24	320
320	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. 2006 , 116, 2695-706	372
319	Applying the discovery of the Philadelphia chromosome. 2007 , 117, 2067-74	83
318	Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. 2008 , 118, 924-34	56
317	Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. 2008 , 118, 2832-44	130
316	Lnk constrains myeloproliferative diseases in mice. 2010 , 120, 2058-69	86
315	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. 2010 , 120, 3578-93	153
314	Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. 2013 , 123, 2169-82	35
313	Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. 2013 , 123, 2576-89	49
312	JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. 2018 , 128, 789-804	47
311	Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms. 2018 , 128, 125-140	17
310	Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. 2019 , 129, 1596-1611	40
309	Platelets and Thrombosis in Myeloproliferative Diseases. 2005 , 2005, 409-415	4
308	JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. 2013 , 2013, 529-537	4

307	Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. 2019 , 8,	12
306	Management of thrombocythemia. 2014 , 3, 227	3
305	MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. 2006 , 3, e270	1022
304	Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. 2006 , 1, e18	188
303	Splenectomy normalizes hematocrit in murine polycythemia vera. 2009 , 4, e7286	3
302	Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. 2010 , 5, e8893	25
301	Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. 2011 , 6, e26534	13
300	A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. 2012 , 7, e33100	17
299	Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. 2012 , 7, e43437	18
298	Gain-of-function of Stat5 leads to excessive granulopoiesis and lethal extravasation of granulocytes to the lung. 2013 , 8, e60902	3
297	Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. 2013 , 8, e70536	33
296	Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 2013 , 8, e77819	7
295	Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVT1-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. 2014 , 9, e84746	21
294	Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). 2014 , 9, e90299	38
293	Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. 2014 , 9, e99017	2
292	JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden. 2015 , 10, e0116636	4
291	Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation. 2015 , 10, e0122003	3
290	Methotrexate Is a JAK/STAT Pathway Inhibitor. 2015 , 10, e0130078	86

289	The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. 2016 , 11, e0154183	14
288	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. 2017 , 12, e0176181	49
287	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. 2017 , 12, e0183620	27
286	Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplazmele mieloproliferative Philadelphia-negative. 2016 , 24, 279-289	2
285	What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?. 2011 , 17, 12-6	5
284	JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. 2007 , 30, 336-338	7
283	Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. 2017 , 8, 41876-41889	21
282	Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. 2014 , 5, 9564-76	29
281	The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. 2015 , 6, 40141-57	27
280	Biology of Myeloproliferative Malignancies. 2016 , 9, 314-325	7
279	Myelofibrosis Models: Literature Review and Own Data. 2017 , 10, 75-84	2
278	Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. 2019 , 26, 1328-1350	8
277	Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. 2016 , 17, 4647-4653	6
276	[JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation]. 2010 , 138, 614-8	1
275	Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. 2009 , 7, 204-9	11
274	Erythrocytosis: genes and pathways involved in disease development. 2021 , 19, 518-532	4
273	JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population. 2019 , 20, 3611-3615	5
272	[JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms]. 2010 , 30, 567-74	4

271	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. 2010 , 2,	3
270	Hemoglobinopathies. 2018 , 64, 476-487	2
269	JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling. 2020 , 7, 61-70	1
268	[Clinical significance of JAK2?CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]. 2017 , 38, 295-300	3
267	Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders. 2006 , 21, 219-24	3
266	Recent insights regarding the molecular basis of myeloproliferative neoplasms. 2020 , 35, 1-11	14
265	Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis. 2015 , 4, 107-15	3
264	Rare cancers: Challenges & issues. 2017 , 145, 17-27	25
263	Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India. 2019 , 8, 127-129	2
262	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. 2015 , 47, 607-15	76
261	Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. 2016 , 33, 187-95	5
260	Hematological disorders and pulmonary hypertension. 2016 , 8, 703-718	32
259	Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. 2011 , 33, 417-24	13
258	Molecular biology of Philadelphia-negative myeloproliferative neoplasms. 2012 , 34, 150-5	12
257	The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms. 2013 , 35, 278-9	2
256	Polycythemia vera: new clinicopathologic perspectives. 2006 , 130, 1126-32	17
255	Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis. 2006 , 130, 1133-43	22
254	Essential thrombocythemia: a review of diagnostic and pathologic features. 2006 , 130, 1144-50	25

- 253 Transformation of polycythemia vera to chronic myelogenous leukemia. **2007**, 131, 1719-24 23
- 252 Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. **2015**, 16, 2219-25 10
- 251 Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. **2021**, 13, 0
- 250 Platelet Heterogeneity in Myeloproliferative Neoplasms. **2021**, 41, 2661-2670 2
- 249 New Markers of Disease Progression in Myelofibrosis. **2021**, 13, 1
- 248 From Metcalf to myeloproliferative neoplasms - a personal journey. **2021**, 0
- 247 Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells. **2021**, 0
- 246 Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. **2021**, 13, 0
- 245 Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective. **2021**, 5, 100081 0
- 244 Bcr-Abl and Signal Transduction. **2007**, 15-35
- 243 Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked. **2007**, 385-398
- 242 Thrombocytosis and Essential Thrombocythemia. **2007**, 1009-1028
- 241 FLT3: A Prototype Receptor Tyrosine Kinase Target in AML. **2007**, 247-261
- 240 Thrombocythémie essentielle. Apport de la mutation V617F de JAK2 pour la stratégie diagnostique, la physiopathologie et les modalités évolutives. **2007**, 191, 535-548
- 239 Manifestations vasculaires au cours des thrombocythémies essentielles. **2007**, 191, 519-533
- 238 Fungal Rhinosinusitis. **2007**, 197-214 1
- 237 Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan. **2008**, 31, 427-430
- 236 Myeloproliferative Disorders. **2008**, 2261-2278

- 235 Transcription Factors STAT5 and STAT3. **2008**, 257-290
- 234 Mouse Models of Myeloproliferative Disease Associated with Mutant JAK2 Tyrosine Kinase: Insights into Pathophysiology and Therapy. **2008**, 1-20
- 233 Reactive versus neoplastic bone marrow: problems and pitfalls. **2008**, 132, 587-94 14
- 232 Hematologic malignancies: correlation between morphology, phenotype,. **2008**, 125-242
- 231 Molecular Basis of Lymphoid and Myeloid Diseases. **2009**, 265-290
- 230 Molecular Assessment of Human Disease in the Clinical Laboratory. **2009**, 605-612
- 229 Targeted Approaches to Drug Development. **2009**, 57-98 0
- 228 Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. **2009**, 1, e2009033 3
- 227 Development of Test System for Detection of V617F Mutation of JAK2 Gene in Patients with Chronic Myeloproliferative Disorders. **2009**, 5, 59-63 1
- 226 Precursor T-Cell Neoplasms. **2010**, 329-346
- 225 Recent advances in the diagnosis and treatment of myeloproliferative neoplasms. **2010**, 21, 514-518
- 224 Essential Thrombocythemia (ET). **2010**, 15-50
- 223 Molecular Pathogenesis of Nonchronic Myeloid Leukemia Myeloproliferative Neoplasms. **2010**, 395-403
- 222 Introduction to Classic Chronic Myeloproliferative Disorders (CMPDs) [Molecular and Cellular Biology. **2010**, 1-13
- 221 The role of FasR/FasL system in pathogenesis of myeloproliferative neoplasms. **2010**, 62, 223-230
- 220 Detection of V617F mutation of gene jak2 at patients with chronic myeloproliferative neoplasms. **2010**, 26, 214-217 1
- 219 Diagnosis and Classification of the BCR-ABL1-Negative Myeloproliferative Neoplasms. **2011**, 1-37
- 218 Blastic Transformation of Classic Myeloproliferative Neoplasms. **2011**, 169-180

217 JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms. **2011**, 151-167

216 Myeloproliferative Neoplasms. 686-709

215 The Myelodysplastic Syndromes. **2011**, 656-671

214 Bone marrow. **2011**, 1927-2012

213 Principles of Classification of Myeloid Neoplasms. **2011**, 649-655

212 Myeloproliferative Neoplasms. **2011**, 698-732

1

211 Myeloproliferative Neoplasms. **2011**, 123-131

210 Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. 362-372

209 Molecular Diagnosis of Hematopoietic Neoplasms. **2011**, 1415-1440

208 Traditional Diagnostic Approaches. 29-42

1

207 Myeloproliferative Neoplasms. 47-61

206 Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification. **2012**, 37-45

205 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy. **2012**, 203-214

204 Somatic Alterations and Targeted Therapy. **2012**, 51-101

203 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. **2012**, 131-145

202 Ongoing Clinical Trials in Myeloproliferative Neoplasms. **2012**, 215-232

201 Update on the Biology of Myeloproliferative Neoplasms. **2012**, 3-10

200 Intracellular Messengers. **2012**, 286-306

- 199 Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy. **2012**, 241-276
- 198 Myeloproliferative and Overlap Myelodysplastic/Myeloproliferative Neoplasms. **2012**, 479-522
- 197 The Management and Outcome of Pregnancy in Patients with Myeloproliferative Neoplasms. **2012**, 185-195
- 196 Myeloproliferative Neoplasms. **2012**, 129-140
- 195 Molecular Diagnosis in Hematopathology. **2012**, 679-726
- 194 Particle in Cell Simulation. **2012**, 187-189
- 193 Hematopoietic Malignancies. **2012**, 1371-1396
- 192 The Use of JAK-specific inhibitors as chemical biology tools. **2013**, 967, 99-113 2
- 191 Somatic Mutations in Polycythaemia Vera and Other Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
- 190 Molecular Diagnostics of Myeloid Neoplasms. **2014**, 557-587
- 189 Complex Diagnosis of Myeloid Neoplasms in Regional Oncological Centers. **2013**, 9, 61-72
- 188 Thrombocytosis. **2014**, 133-150
- 187 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2
- 186 Chapter 15:The Discovery and Development of Ruxolitinib for the Treatment of Myelofibrosis. **2014**, 419-439
- 185 Molecular Testing in Hematologic Malignancies. **2014**, 135-167
- 184 Myeloproliferative Neoplasms. **2014**, 1929-1943.e4
- 183 Other Secondary Causes. **2015**, 141-162
- 182 Next-Generation Sequencing Applications in Head and Neck Oncology. **2015**, 401-422

- 181 The Management and Outcome of Pregnancy in Patients with Myeloproliferative Neoplasms. **2015**, 315-325
- 180 Frequency and Clinicohematologic Characteristics of MPLW515 Mutations in Patients with Myeloproliferative Neoplasms. **2015**, 5, 1 1
- 179 Usefulness of BCSH Criteria for Diagnosing Japanese Polycythemia Vera. **2015**, 61, 287-293
- 178 Platelet Disorders: Diagnostic Tests and Their Interpretations. **2016**, 171-183
- 177 Targeting Upstream Janus Kinases. **2016**, 163-175
- 176 Polycythemia Vera: New Diagnostic Concept and Its Types. **2016**, 9, 115-122 0
- 175 Myeloproliferative neoplasms and JAK2 mutations. **2016**, 136, 1889-1894
- 174 Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. **2016**, 33, 94-101 3
- 173 Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
- 172 Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. **2016**, 2016, 552-560 1
- 171 Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia. **2017**, 10, 402-408 1
- 170 Essential Thrombocythemia. **2018**, 141-154
- 169 Updates in Polycythemia Vera. **2018**, 115-139
- 168 Jak/STAT Signaling in Head and Neck Cancer. **2018**, 155-184 0
- 167 FEATURES OF HEMATOLOGICAL PARAMETERS IN CALR-POSITIVE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. **2018**, 1.1, 227
- 166 Single-cell analyses reveal aberrant pathways for megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. 0
- 165 EARLY DETECTION OF JAK2V617F MUTATION AS AN INDEPENDENT RISK FACTOR FOR SPLANCHNIC VENOUS THROMBOSIS IN ACUTE ABDOMEN. **2019**, 6, 2051-2054
- 164 Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome. **2019**, 3, 053-059

163 Thrombophilia and Primary Budd-Chiari Syndrome. **2020**, 57-71

162 Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms.

161 Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia. **2019**, 219, 440-444

160 Hematological System Diseases. **2020**, 547-568

159 Study of the p.V617F and Exon 12 Mutations in JAK2 Gene Among Iranian Chronic Myeloproliferative Patients. **2019**, 3,

158 Clinical Spectrum of Primary Polycythaemia and Its Complications - Experience from a Single Center in Karnataka. **2020**, 9, 2461-2465

157 New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. **2021**, 57,

156 Thrombocytosis caused by abnormal molecular chaperone. **2020**, 31, 491-497

155 Calreticulin mutations in myeloproliferative neoplasms. **2021**, 365, 179-226

2

154 Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. **2021**, 365, ix-xx

153 The JAK2 mutation. **2021**, 365, 117-162

0

152 Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. **2021**, 365, 1-69

2

151 Targeting Pathways in GI Malignancies. **2020**, 1-14

150 The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. **2020**, 13, 2634853520978210

5

149 STAT5 and STAT5 Inhibitors in Hematological Malignancies. **2019**, 19, 2036-2046

1

148 Identification of <i>JAK2</i> (V617F) Mutation in Myeloproliferative Neoplasms by Using Allele Specific Polymerase Chain Reaction (AS-PCR). **2020**, 10, 273-282

0

147 Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice. **2020**, 136, 106-118

5

146 Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. **2021**,

0

- 145 Mutated JAK2 signal transduction in human Induced Pluripotent Stem Cell (iPSC)-derived Megakaryocytes. **2021**, 1-9
- 144 The Myeloproliferative Syndromes. **2007**, 137-154
- 143 Tyrosine Kinase Inhibitors. **2007**, 477-508
- 142 BCR-ABL-Negative Chronic Myeloid Leukemia. **2007**, 219-233
- 141 Chronic Idiopathic Myelofibrosis. **2007**, 253-276
- 140 Polycythemia Vera [Clinical Aspects. **2007**, 277-296
- 139 Polycythemia Vera and Other Polycythemic Disorders [Biological Aspects. **2007**, 297-319
- 138 Essential Thrombocythemia. **2007**, 321-348
- 137 A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. 1
- 136 Integrated Ligand and Structure based approaches towards developing novel Janus Kinase 2 inhibitors for the treatment of myeloproliferative neoplasms.
- 135 JAK2 V617F: a single mutation in the myeloproliferative group of disorders. **2006**, 75, 112-9 16
- 134 The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels. **2009**, 7, 111-6 11
- 133 Telomere dysfunction in human diseases: the long and short of it!. **2009**, 2, 528-43 20
- 132 Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. **2007**, 1, 129-38 5
- 131 Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. **2010**, 2, 219-23 2
- 130 Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression. **2011**, 1, 752-62 2
- 129 Emerging therapeutic options for myelofibrosis: a Canadian perspective. **2012**, 2, 170-86 3
- 128 Molecular genetics of myelofibrosis and its associated disease phenotypes. **2014**, 8, 53-64 6

127	The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis. 2014 , 4, 53-72	8
126	JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. 2016 , 10, 70-8	3
125	Quantitative analyses of myelofibrosis by determining hydroxyproline. 2015 , 2, 2	2
124	The extracellular signal-regulated kinase 1/2 modulates the intracellular localization of DNA methyltransferase 3A to regulate erythrocytic differentiation. 2020 , 12, 1016-1030	4
123	[JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm]. 2015 , 36, 191-5	1
122	Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life. 2017 , 31, 521-9	2
121	Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. 2021 ,	0
120	Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management. 2021 , 19, 1362-1364	
119	MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera. 2021 , 11, 22483	
118	Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. 2021 , 115, 198	2
117	The JAK/STAT signaling pathway: from bench to clinic. 2021 , 6, 402	47
116	The MPL mutation. 2021 , 365, 163-178	1
115	Phenformin increases early hematopoietic progenitors in the Jak2 murine model.. 2022 , 1	
114	Is It Possible to Predict Clonal Thrombocytosis in Triple-Negative Patients with Isolated Thrombocytosis Based Only on Clinical or Blood Findings?. 2021 , 10,	
113	Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells.. 2022 , 73, 307-320	0
112	CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythaemia.. 2022 ,	0
111	Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.. 2022 , 23,	1
110	Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.. 2021 , 12, 788891	1

109	Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.. 2022 ,	4
108	Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.. 2022 , 23,	0
107	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.. 2022 , 11,	0
106	Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis. 2022 , 101, 1	
105	Clinical impact of glycans in platelet and megakaryocyte biology.. 2022 ,	1
104	JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.. 2022 , 15,	1
103	Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.. 2022 ,	1
102	PD-L1 Overexpression Correlates with JAK2-V617F Mutational Burden and Is Associated with 9p Uniparental Disomy in Myeloproliferative Neoplasms.. 2022 ,	1
101	JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.. 2022 , 12, 13	1
100	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.. 2022 ,	1
99	Inflammasome Activation in Myeloid Malignancies-Friend or Foe?. 2021 , 9, 825611	1
98	Pathogenic 'germline' variants associated with myeloproliferative disorders in apparently normal individuals: inherited or acquired genetic alterations?. 2021 ,	0
97	Targets in MPNs and potential therapeutics.. 2022 , 366, 41-81	
96	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.. 2022 , 366, 83-124	2
95	Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives.. 2022 , 366, ix-xx	
94	Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.. 2022 , 12,	0
93	Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.. 2022 ,	0
92	Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.. 2022 ,	0

91	CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis.	1
90	A Rare Co-Occurrence of Triple Mutations in , and in the Same Patient with Myelofibrosis.. 2022 , 2022, 4579122	
89	Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2-induced myeloproliferative neoplasms.. 2022 , 12, 37	
88	HMGA1 Chromatin Regulators Induce Transcriptional Networks Involved in GATA2 and Proliferation During MPN Progression.. 2022 ,	0
87	Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.. 2022 ,	
86	Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.. 2022 , 1	3
85	In vivo monitoring of Polycythemia Vera development reveals carbonic anhydrase 1 as a potent therapeutic target.. 2022 ,	
84	Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing.. 2022 , 13, 850045	
83	Genetic Background of Polycythemia Vera.. 2022 , 13,	1
82	Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation.. 2022 , 376, eabn8933	11
81	Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.. 2022 , 13, 1750	0
80	Myelofibrosis: genetic characteristics and the emerging therapeutic landscape.. 2021 ,	3
79	Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice. 2021 , 16, e0251995	1
78	Essential Thrombocythemia in Children and Adolescents. 2021 , 13,	0
77	NGS Evaluation of a Bernese Cohort of Unexplained Erythrocytosis Patients.. 2021 , 12,	0
76	A pilot study examining the efficacy of hochuekkito for improving quality of life in patients with myeloproliferative neoplasms.. 2022 ,	
75	BMP2/SMAD pathway activation in JAK2/p53-mutant Megakaryocyte/Erythroid Progenitors Promotes Leukemic Transformation.. 2022 ,	1
74	Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors.. 2022 , 10,	

73	Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.. 2022 , 23,	1
72	Leveraging single cell sequencing to unravel intra-tumour heterogeneity and tumour evolution in human cancers.. 2022 ,	0
71	Data_Sheet_1.pdf. 2020 ,	
70	Data_Sheet_1.PDF. 2019 ,	
69	Image_1.PDF. 2018 ,	
68	JAK inhibitors and COVID-19.. 2022 , 10,	4
67	Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.. 2022 , 13, 819-826	0
66	Myeloproliferative neoplasms - a global view.. 2022 ,	1
65	Advances in Janus-Associated Kinase Inhibitor-Based Therapies for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. 2022 , 2, 179-194	0
64	Iron homeostasis governs erythroid phenotype in Polycythemia Vera.	
63	Understanding myeloproliferative disorders. 175573802210964	
62	Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity.	
61	Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. 2022 , 213, S107-S112	0
60	Integrated Single-Cell Genotyping and Chromatin Accessibility Charts JAK2V617F Human Hematopoietic Differentiation.	0
59	The Odyssey of Pacritinib in Myelofibrosis.	4
58	Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. 2022 , 39,	
57	Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.	0
56	Asking Existing Data the Right Questions: Data Mining as a Research Option in Low- and Middle-Income Countries. 2022 , 69-74	

55	Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. 1-9	
54	Clonal hematopoiesis in clinical practice: walking a tightrope. 1-9	o
53	Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.	
52	JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. 10,	o
51	Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.	
50	Recent advances in targeting protein kinases and pseudokinases in cancer biology. 10,	1
49	The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms. 2022 , 102698	
48	Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells. 2022 , 81-109	o
47	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. 2022 , 12, 1135	1
46	A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. 2022 , 11, 4663	o
45	Contemporary and future strategies in polycythemia vera. 2022 , 101370	
44	Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F+ myelofibrosis. 13,	
43	Targeted NGS analysis of the canonical genes in 274 Indian patients with suspected myeloproliferative neoplasms: An Indian diagnostic laboratory perspective. 2022 , 9, 248-252	
42	Myeloproliferative Neoplasms. 2022 ,	o
41	Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.	o
40	Simultaneous detection of JAK2 , CALR , and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy.	o
39	Development of an in-house real time q-PCR assay for the detection of jak2 mutations in myeloproliferative neoplasms.	o
38	Inferring the initiation and development of myeloproliferative neoplasms. 2022 , 119,	2

37	Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 2022 , 20, 1033-1062	4
36	Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital. Volume 13, 495-503	0
35	Clonal Hematopoiesis, Somatic Mosaicism, and Age-Associated Disease.	1
34	Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms.	0
33	HOXA9 has the hallmarks of a biological switch with implications in blood cancers. 2022 , 13,	0
32	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
31	Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.	0
30	A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.	1
29	Management of polycythemia vera: a survey of treatment patterns in Italy.	0
28	Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms. 2022 , 156, 113884	0
27	Molecular Pathogenesis of Myeloproliferative Neoplasms.	2
26	Recurrent missense variants in clonal hematopoiesis-related genes present in the general population.	0
25	Recombinant Interferon- γ in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. 2022 , 14, 5495	0
24	Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients. 2022 , 61, 3323-3328	0
23	The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant. 2023 , 102, 110537	0
22	Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. 2022 ,	0
21	Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. PHARMREV-AR-2022-000612	0
20	Molecular dissection of Janus kinases as drug targets for inflammatory diseases. 13,	0

- 19 Unilateral panuveitis secondary to JAK2 mutation-associated lymphoproliferative disease. **2022**, 15, e253572 ○
- 18 The JAK/STAT/BOCS Signaling Cascade. **2016**, 162-179 ○
- 17 Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. **2023**, 30, 45-52 ○
- 16 Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. ○
- 15 WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen. ○
- 14 Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event in a population based cohort study. ○
- 13 A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation. **2023**, 250, 115198 ○
- 12 Exploration and identification of anoikis-related genes in polycythemia vera. 14, ○
- 11 Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?. **2023**, 15, 1348 ○
- 10 Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases. 13, ○
- 9 Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms. **2023**, 24, 4497 ○
- 8 Essenzielle Thrombozythämie und Polycythaemia vera. **2023**, 29, 296-304 ○
- 7 The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms. **2023**, 24, 4860 ○
- 6 Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis. **2023**, 15, 1785 ○
- 5 Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke. **2023**, 54, 938-946 ○
- 4 Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12). ○
- 3 An investigation of JAK2 mutation in patients with ulcerative colitis with a history of thrombosis. **2023**, 7, 245-248 ○
- 2 Polycythemia vera: aspects of its current diagnosis and initial treatment. **2023**, 16, 253-266 ○

1 Advances in molecular evaluation of myeloproliferative neoplasms. **2023**,

o